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ABSTRACT OF THE DISSERTATION 
The Mechanism of Hyper Daptomycin Resistance in Corynebacterium striatum and 
Daptomycin’s Mechanism of Action  
by 
Nicholas K. Goldner 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2018 




Daptomycin, a last line-of-defense antibiotic for treating Gram-positive infections, is experiencing 
clinical failure against important infectious agents, including Corynebacterium striatum. The 
recent transition of daptomycin to generic antibiotic status is projected to dramatically increase 
availability, use, and clinical failure. Despite daptomycin’s more than 30-year history as an 
important antibiotic, four major questions were left unanswered. 1) How do bacteria become 
hyper-resistant to daptomycin? 2) What is the in vivo membrane target of daptomycin? 3) How 
does daptomycin interact with the membrane? 4) What is daptomycin’s mechanism of killing?  
These four questions have plagued the daptomycin field, and even now conflicting mechanisms 
have been reported in the literature. This thesis has focused on teasing apart the intricacies of these 
four questions.  
xiv 
 
To answer the first two questions, regarding 1) hyper-resistance to daptomycin and 2) the in vivo 
membrane target of daptomycin, we identified the mechanism of high-level daptomycin resistance 
in C. striatum, which helped us to identify phosphatidylglycerol as the in vivo target of daptomycin.  
Here, we confirm the genetic mechanism of high-level daptomycin resistance (HLDR, MIC > 256 
µg/mL) in C. striatum, which evolved within a patient during daptomycin therapy, a phenotype 
recapitulated in vitro. In all eight independent cases tested, loss of function mutations in 
phosphatidylglycerol synthase (pgsA2) were necessary and sufficient for high-level daptomycin 
resistance. Through lipidomic and biochemical analysis, we demonstrate that the activity of 
daptomycin is dependent on membrane phosphatidylglycerol (PG) concentration. Until now, the 
verification of PG as the in vivo target of daptomycin has proven difficult, as tested cell model 
systems were not viable without membrane PG. C. striatum becomes high-level daptomycin 
resistant by removing PG from the membrane and changing membrane composition to maintain 
viability. This work demonstrates that a single loss of function mutation in pgsA2, and the loss of 
membrane PG is necessary and sufficient to produce high-level resistance to daptomycin in C. 
striatum and result in daptomycin’s clinical failure.   
Even though there have been numerous studies looking at daptomycin’s interaction with the 
membranes, several problems with the model systems and methods used have plagued the field, 
casting doubt and uncertainty on 3) how daptomycin interacts with the membrane, and 4) how 
daptomycin kills bacteria. Previous studies have used model membranes that are too large (giant 
unilamellar vesicles that are 100x bigger than bacteria), indirect measurements through 
fluorescence, unknown PG and acyl tail requirements for model systems, and chemically altered 
daptomycin that no longer behaves like daptomycin (as indicated by a drastic increase in minimum 
inhibitory concentration compared to native daptomycin). The data reported here demonstrates a 
xv 
 
shift in how we understand the interactions of daptomycin with the bacterial cell. Once daptomycin 
binds to the membrane, it is stably integrated in a calcium- and PG-dependent manner (~1:1 
daptomycin to PG).  It then recruits or co-localizes with other daptomycin molecules to form stable 
pores with an approximate Stokes radius of 8 nm, which is far larger than the previously reported 
ion channels. The resulting pore allows metabolites, ions and other intracellular components to 
exit the cell.  When enough PG is present in the bacterial membranes, enough daptomycin pores 
can be formed to release necessary metabolites, ultimately resulting in cell death.  
In summary, 1) bacteria become high-level resistant to daptomycin by removing daptomycin’s 2) 
in vivo target, phosphatidylglycerol (PG), from the membrane. 3) In the presence of PG, 
daptomycin binds and integrates into the membrane to form a large pore that 4) disrupts the 
membrane potential and allows intracellular metabolites, ions and other important molecules to 




Chapter 1: Introduction to Daptomycin  
  Antibiotic resistance is an extreme, worsening and long-term burden to human health, and 
is exacerbated by poor antibiotic stewardship and stalled drug discovery to treat new emerging 
diseases. Bacteria evolve resistance to antibiotics by acquiring antibiotic resistance genes 
(horizontal gene transfer) or by genetic changes that result in antibiotic resistance (vertical gene 
transfer). Additionally, increased antibiotic use over the past century has enabled multiple clinical 
pathogens to acquire resistance to the best antibiotics available (Krawczyk et al., 2004; Liu et al., 
2012; McElvania TeKippe et al., 2014; Michael et al., 2015; Teatero et al., 2015; Teo et al., 2015). 
This poses a grave clinical concern with no immediately clear answer. Antibiotic resistance is so 
pervasive in the bacterial community that every major antibiotic drug class currently in use has 
reports of pathogens with high-level resistance (Baym et al., 2016; Palmer and Kishony, 2013). 
What bacteria do naturally—evolve to adapt to their environment—costs the United States more 
than 55 billion dollars a year and kills more than 40 thousand people annually (GELBAND et al., 
2015; Prevention, 2013). By 2050, these tiny ubiquitous organisms will have cost the global 
economy in excess of 100 trillion dollars and erased hundreds of millions of people from the world 
(12420, 2015; Dynamics, 2015; LLP, 2014; O'Neill, 2014).  
Bacterial acquisition of antibiotic resistance to drugs is drastically outstripping our capacity 
to produce novel antibiotics. Antibiotics that have reportedly very low levels of resistance, such as 
daptomycin, are starting to fail (Cesar A. Arias et al., 2001; Hines et al., 2017; McElvania TeKippe 
et al., 2014).  Accordingly, elucidating novel mechanisms of antibiotics resistance has extreme 
clinical relevance, to help extend the lifetimes of important chemotherapeutics (Rizvi et al., 2015) 
and identify novel druggable targets (Gonzales et al., 2015). This is especially important as 




With increased usage of generic antibiotics comes an increased risk of antibiotic resistance, which 
leads to dramatically reduced clinical efficacy of the drug, and an associated increase in patient 
death due to the ineffectiveness of previously successful treatments.  
   Daptomycin, an antibiotic discovered over thirty years ago, forms a last line-of-defense 
against deadly pathogens (Lakey and Lea, 1986). As a cyclic-lipopeptide, daptomycin belongs to 
a unique class of antibiotics and is backed by extensive research and testing efforts that led to 
approval for use in humans (Baltz, 2009; Taylor and Palmer, 2016). It has been used judiciously 
and serves an important role in treating antibiotic-resistant, Gram-positive bacterial infections. 
Although its mechanism of action has remained unclear, daptomycin targets the bacterial 
membrane, resulting in leakage of large molecules (determined using intracellular dyes) but not 
complete cell lysis (Cotroneo et al., 2008; Hobbs et al., 2008). Several mechanisms of action have 
been proposed, including pore formation (Zhang et al., 2014a), increased membrane permeability 
(Straus and Hancock, 2006), membrane deformation (Chen et al., 2014), division inhibition 
(Muller et al., 2016) and peptidoglycan targeting (Allen et al., 1987). The first occurrences of 
clinical resistance to daptomycin in Staphylococcus aureus were incremental (Yang et al., 2013; 
Yang et al., 2010), and easily managed in patients through small daptomycin dose increases (Weis 
et al., 2008). The lack of resistance to high doses was ascribed to the target of daptomycin being 
the cell membrane (Alborn et al., 1991; Allen et al., 1991), with several in vitro studies identifying 
phosphatidylglycerol as its specific lipid target (Muraih et al., 2012). It was incorrectly assumed 
that bacteria would have difficulty making large scale shifts in membrane lipid composition 
(Hachmann et al., 2011; Hines et al., 2017), and thus would be unable to develop resistance.  
In artificial membrane systems, daptomycin preferentially binds phosphatidylglycerol 




most likely proposed mechanism of action is that daptomycin forms 1:1 daptomycin:Ca2+ micelles 
(Jung et al., 2008; Jung et al., 2004; Scott et al., 2007), which dissociate in the presence of PG-
containing membranes and then bind to the membrane via the hydrophobic 10-C acyl tail of 
daptomycin. Once bound, daptomycin integrates into the hydrophobic core of the bilayer (Jung et 
al., 2004; Lakey and Ptak, 1988[Jung, 2008 #8822) at a proposed ~1:1 ratio of PG to daptomycin 
(Lee et al., 2017). However, determining the PG:daptomycin interaction stoichiometry has proven 
difficult, with various methods and lipid preparations yielding predicted stoichiometries ranging 
from 1:1 in bicelles to 2:1 in liposomes (Zhang et al., 2013) (Muraih and Palmer, 2012). Beyond 
this point, it is unclear how daptomycin kills bacterial cells; however, there is substantial evidence 
in favor of membrane disruption, eventually resulting in cell death (Laganas et al., 2003; Mascio 
et al., 2007; Pogliano et al., 2012; Silverman et al., 2003; Taylor et al., 2017a; Zhang et al., 
2014a,[Taylor, 2017 #9958). Previous elegant experiments have begun to dissect the binding and 
conformational changes observed in membrane-associated daptomycin (Jung et al., 2008; Jung et 
al., 2004; Lee et al., 2017).  
 
As recently as 2014, it was shown that daptomycin permeability was size- and cation-
selective (Alborn et al., 1991; Allen et al., 1991; Zhang et al., 2014a). However, two shortcomings 
of these findings require resolution. First, at physiological concentrations of daptomycin (between 
the minimum inhibitory concentration (MIC) of 0.064 µg/mL and the peak reported serum 
concentrations of 100 µg/mL) of daptomycin (Antachopoulos et al., 2012; McElvania TeKippe et 
al., 2014), the mechanisms of membrane dysregulation were inconclusive. This could be 




efforts to confirm ion leakage and pore formation in vivo using the Bacillus subtilis model (Muller 
et al., 2016) yielded results contrary to the proposed mechanisms identified in vitro.  Studying the 
mechanism of antibacterial action of daptomycin and other antimicrobial peptides will thus require 
a holistic approach, calling on genomics, transcriptomics, metabolomics and lipidomics, as well 
as classical biochemical and biophysical techniques.  
 Recent clinical reports of treatment failures have emerged with target pathogens exhibiting 
>2000-fold increases in daptomycin resistance (Akins et al., 2015; Garcia-de-la-Maria et al., 2013; 
McElvania TeKippe et al., 2014), often over rapid time-scales (hours to a few days of treatment), 
which are beginning to challenge daptomycin’s efficacy. These failures are expected to expand as 
daptomycin transitions to generic status (OptumRx, 2016) , as availability for clinical use 
increases. Case in point, C. striatum is an emerging opportunistic pathogen that colonizes the skin 
much like S. aureus. C. striatum’s ability to rapidly transition from susceptible to resistant to 
daptomycin poses a serious epidemiological threat to our healthcare system (Chatzopoulou et al., 
2016). However, these two pathogens evolve daptomycin resistance in mechanistically distinct 
ways. In S. aureus, low-level, step-wise accumulations in resistance phenotypes are responsible 
for low (Minimum Inhibitory Concentration (MIC): 2-4 µg/ml) and intermediate (MIC: 4-8 µg/ml) 
daptomycin resistance. The majority of these observations come from pathogenic S. aureus, which 
was the first approved therapeutic target for daptomycin (Sauermann et al., 2008). Accumulation 
of multiple single nucleotide polymorphisms (SNPs) in the yycFGHI operon in S. aureus has 
resulted in 2-6-fold increases in daptomycin resistance through cell wall thickening and alteration 
of membrane charge (Bayer et al., 2013; Gaupp et al., 2015; Mishra et al., 2014; Quinn et al., 2007; 
Raad et al., 2007; Reyes et al., 2015). Increases in positively charged membrane phospholipids, 




the MIC. Additionally, mutations that alter lipid translocation, decrease membrane fluidity, and 
thickening of the cell wall have led to low-level (3-6 fold) increases in daptomycin resistance 
(Mishra et al., 2014; Mishra et al., 2009). Mutations associated with the above physiological 
changes in pathogenic S. aureus have all led to small stepwise increases (2-6 fold) in resistance 
over long periods of time (weeks of treatment) and lose resistance to daptomycin when no longer 
under daptomycin’s selection pressure(Li et al., 2017). In contrast, some environmental 
Streptomyces species have been shown to inactivate daptomycin (D'Costa et al., 2012; Vanessa M. 
D’Costa, 2006) enzymatically; clinical isolates have not used this mechanism to date.  
The first report of higher levels (~20-fold over wild-type) of daptomycin resistance come 
from laboratory adaptive evolution experiments with the non-pathogenic, soil bacterium, Bacillus 
subtilis (Hachmann et al., 2011). Daptomycin resistant B. subtilis was found to harbor SNPs in 44 
genes, including predicted reduction/loss of function mutations in phosphatidylglycerol synthase 
A (pgsA), an essential enzyme for phosphatidylglycerol (PG) synthesis (Hachmann et al., 2009; 
Hachmann et al., 2011). Characterization of the lipid membrane revealed a reduction in PG content 
from 30% in the wild-type to 10% in the resistant mutant. Consistent with the lack of complete 
ablation of PG in the membrane, attempts to knock out pgsA alone genetically were not successful, 
due to presumed essentiality of PG in B. subtilis (Hachmann et al., 2011). Nevertheless, studies of 
daptomycin’s target to date corroborate in vivo the importance of PG in daptomycin activity 
(Hachmann et al., 2009; Hachmann et al., 2011; Hines et al., 2017). Indeed, a recent comparative 
genomic and lipidomic study of S. aureus, C. striatum, and Enterococcus faecalis indicated 
mutations in PG synthase and subsequent lack of PG synthesis confers daptomycin 
resistance(Hines et al., 2017)(Hines et al., 2017)(Hines et al., 2017)(Hines et al., 2017)(Hines et 




Over the past few years, there has been a steady increase in reports of even higher-level 
daptomycin resistance (³4000 fold increase in resistance) in a number of clinical pathogens, 
including viridians group Streptococci (Akins et al., 2015), Enterococcus faecium (Humphries et 
al., 2012), and C. striatum (McElvania TeKippe et al., 2014). This high-level daptomycin 
resistance (HLDR)—defined here as having a MIC ³ 256 µg/ml daptomycin—was first observed 
in C. striatum, in a patient with native valve endocarditis in 2012 (Tran et al., 2012). In 2014, a 
clinical laboratory reported in vivo evolution of HLDR C. striatum in a patient with an infected 
left ventricular assist device, during 17 days of daptomycin therapy (McElvania TeKippe et al., 
2014). Evolution of HLDR was recapitulated in vitro in 100% of tested C. striatum isolates (n=50) 
after 24 hours of daptomycin exposure (McMullen et al., 2017a). C. striatum is a Gram-positive 
bacterium which typically resides as a commensal organism on the skin (Oh et al., 2014). However, 
it has become a growing threat to hospital systems and patients as an opportunistic pathogen. 
Indeed, C. striatum has been associated with a plethora of infection types over the past 20 years 
including bacteremia, endocarditis, urinary tract, wound, respiratory, central line, medical device 
and hardware infections (Gomila et al., 2012; Hahn et al., 2016; Mattos-Guaraldi et al., 2015; 
McElvania TeKippe et al., 2014; Souza et al., 2015; Wang et al., 2016; Werth et al., 2016; Wong 
et al., 2010).  
In this dissertation, we use a combination of comparative genomics, transcriptomics, 
lipidomics, metabolomics, electron microscopy and zeta potential to understand daptomycin’s 
effect on wild type and high level daptomycin resistant C. striatum. We verify the in vivo work 
biochemically and biophysically in vitro, using surface plasmon resonance, carboxyfluorescein 
liposome stability assays and resistive pore blocking. We demonstrate that loss of function 




reduced from ~45% to <1% in the membrane, resulting in HLDR. We further demonstrate that in 
wild type C. striatum and artificial liposomes, daptomycin binds to PG in the membrane, forms 
large pores (~8 nm Stokes radius) and allows metabolites, ions and other important molecules to 
leak out of the cell, ultimately killing the bacteria.  Our work demonstrates the important 
considerations needed for designing future lipopeptide antibiotics, that bacterial cells can readily 
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2.1 Abstract 
Daptomycin, a last line of defense antibiotic for treating Gram positive infections, is experiencing 
clinical failure against important infectious agents including Corynebacterium striatum. The 
recent transition of daptomycin to generic status is projected to dramatically increase availability, 
use, and clinical failure. Here we confirm the genetic mechanism of high-level daptomycin 
resistance (HLDR, MIC > 256 µg/mL) in C. striatum, which evolved within a patient during 
daptomycin therapy, a phenotype recapitulated in vitro. In all 8 independent cases tested, loss of 
function mutations in phosphatidylglycerol synthase (pgsA2) were necessary and sufficient for 
high-level daptomycin resistance. Through lipidomic and biochemical analysis we demonstrate 
that daptomycin’s activity is dependent on membrane phosphatidylglycerol (PG) concentration. 
Until now, the verification of PG as the in vivo target of daptomycin has proven difficult since 
tested cell model systems were not viable without membrane PG. C. striatum becomes high-level 
daptomycin resistant by removing PG from the membrane and changing membrane composition 
to maintain viability. This work demonstrates that loss of function mutation in pgsA2 and the loss 







Current trends in increasing antibiotic resistance and decreasing drug development require urgent 
mitigation (Maragakis et al., 2008; O'Neill, 2014; O'Neill, 2015). Antibiotic resistant infections 
claim over 700,000 lives globally, and this annual toll is predicted to swell to 10 million deaths a 
year by 2050 without significant intervention. A growing number of bacterial infections are 
already resistant to virtually all first-line antibiotics (Dynamics, 2015; O'Neill, 2014). Physicians 
are forced to use “last-resort”, broad-spectrum antibiotics more frequently, and resistance to even 
these carefully safeguarded drugs has emerged (Srinivasan, 2017; Srinivasan and Davidson, 2017). 
Daptomycin is one such last-resort non-lytic (Cotroneo et al., 2008) lipopeptide antibiotic, 
effective against both stationary and log phase Gram-positive bacterial pathogens (Mascio et al., 
2007) including Staphylococcus aureus, Enterococcus faecium, and Corynebacterium striatum 
(Humphries et al., 2012; Jorgensen et al., 2003; Jorgensen et al., 1987). Daptomycin integrates 
Ca2+ dependently into the bacterial cell membrane, causing membrane dysfunction that leads to 
K+, Mg2+, and ATP leakage and cell death (Ho et al., 2008; Hobbs et al., 2008). Very low levels 
of resistance were observed during the early phase of daptomycin’s clinical use. Regrettably, 
recent clinical reports of treatment failures have emerged with target pathogens exhibiting >2000-
fold increases in daptomycin resistance (Akins et al., 2015; Garcia-de-la-Maria et al., 2013; 
McElvania TeKippe et al., 2014), often over rapid time-scales (hours to a few days of treatment), 
which are beginning to challenge daptomycin’s efficacy. These failures are expected to expand as 
daptomycin use is predicted to increase dramatically because its recent transition to generic status 





C. striatum is an emerging opportunistic pathogen that colonizes the skin much like S. aureus. C. 
striatum’s ability to rapidly transition from susceptible to resistant to the critical antibiotic 
daptomycin poses a serious epidemiological threat to our healthcare system (Chatzopoulou et al., 
2016). This work establishes a genetic, transcriptomic, lipidomic and biochemical understanding 
of how C. striatum rapidly evolves high-level daptomycin resistance which is mechanistically 
distinct from S. aureus and Streptomyces spp. In S. aureus, low-level, step-wise accumulations in 
resistance phenotypes are responsible for low (Minimum Inhibitory Concentration, MIC: 2-4 
µg/ml) and intermediate (MIC: 4-8 µg/ml) daptomycin resistance. The majority of these 
observations come from pathogenic S. aureus, which was the first approved therapeutic target for 
daptomycin (Sauermann et al., 2008). Accumulation of multiple single nucleotide polymorphisms 
(SNPs) in the yycFGHI operon in S. aureus has resulted in 2-6-fold increases in daptomycin 
resistance through cell wall thickening and alteration of membrane charge (Bayer et al., 2013; 
Gaupp et al., 2015; Mishra et al., 2014; Quinn et al., 2007; Raad et al., 2007; Reyes et al., 2015). 
Increases in positively charged membrane phospholipids, which reduces the affinity of the Ca2+-
conjugated daptomycin for the surface membrane increased the MIC. Additionally, mutations that 
alter lipid translocation, decrease membrane fluidity, and thickening of the cell wall have led to 
low-level (3-6 fold) increases in daptomycin resistance(Mishra et al., 2014; Mishra et al., 2009). 
Mutations associated with the above physiological changes in pathogenic S. aureus have all led to 
small stepwise increases (2-6 fold) in resistance over long periods of time (weeks of treatment) 
and lose resistance to daptomycin when no longer under daptomycin’s selection pressure(Li et al., 
2017). In contrast, some environmental Streptomyces species have been shown to inactivate 
daptomycin (D'Costa et al., 2012; Vanessa M. D’Costa, 2006) enzymatically; clinical isolates have 





The first report of higher levels (~20-fold over wild-type) of daptomycin resistance come from 
laboratory adaptive evolution experiments with the non-pathogenic, soil bacterium, Bacillus 
subtilis (Hachmann et al., 2011). Daptomycin resistant B. subtilis was found to harbor SNPs in 44 
genes, including predicted reduction/loss of function mutations in phosphatidylglycerol synthase 
A (pgsA), an essential enzyme for phosphatidylglycerol (PG) synthesis (Hachmann et al., 2009; 
Hachmann et al., 2011). Characterization of the lipid membrane revealed a reduction in PG content 
from 30% in the wild-type to 10% in the resistant mutant. Consistent with the lack of complete 
ablation of PG in the membrane, attempts to knock out pgsA alone genetically were not successful 
due to presumed essentiality of PG in B. subtilis (Hachmann et al., 2011). Nevertheless, studies of 
daptomycin’s target to date corroborate in vivo the importance of PG in daptomycin activity 
(Hachmann et al., 2009; Hachmann et al., 2011; Hines et al., 2017). Indeed,  a recent comparative 
genomic and lipidomic study of S. aureus, C. striatum, and Enterococcus faecalis indicated 
mutations in PG synthase and subsequent lack of PG synthesis confers daptomycin 
resistance(Hines et al., 2017)(Hines et al., 2017)(Hines et al., 2017)(Hines et al., 2017)(Hines et 
al., 2017)(Hines et al., 2017)(Hines et al., 2017).  
 
Over the past few years, there has been a steady increase in reports of even higher-level 
daptomycin resistance (³4000 fold increase in resistance) in a number of clinical pathogens, 
including viridians group Streptococci (Akins et al., 2015), Enterococcus faecium (Humphries et 
al., 2012), and C. striatum (McElvania TeKippe et al., 2014). This high-level daptomycin 




daptomycin—was first observed in C. striatum, in a patient with native valve endocarditis in 2012 
(Tran et al., 2012). In 2014, a clinical laboratory reported in vivo evolution of HLDR C. striatum 
in a patient with an infected left ventricular assist device, during 17 days of daptomycin therapy 
(McElvania TeKippe et al., 2014). Evolution of HLDR was recapitulated in vitro in 100% of tested 
C. striatum isolates (n=50) after 24 hours of daptomycin exposure (McMullen et al., 2017a). C. 
striatum is a Gram-positive bacterium which typically resides as a commensal organism on the 
skin (Oh et al., 2014). However, it has become a growing threat to hospital systems and patients 
as an opportunistic pathogen. Indeed, C. striatum has been associated with a plethora of infection 
types over the past 20 years including bacteremia, endocarditis, urinary tract, wound, respiratory, 
central line, medical device and hardware infections (Gomila et al., 2012; Hahn et al., 2016; 
Mattos-Guaraldi et al., 2015; McElvania TeKippe et al., 2014; Souza et al., 2015; Wang et al., 
2016; Werth et al., 2016; Wong et al., 2010). Here we use a combination of comparative genomics, 
transcriptomics, lipidomics, electron microscopy, and biochemical lipid and liposome 
characterization to elucidate the mechanism of HLDR evolved in C. striatum both within patients 
and in vitro. We demonstrate that loss of function mutations in pgsA2 results in PG, the primary 
target of this last-resort drug, to be reduced from ~45% to <1% in the membrane resulting in 
HLDR. Our work demonstrates the important consideration for designing future antibiotics that 
bacterial cells can readily manipulate membrane lipid composition to effectively evade lipid 
targeted lipopeptides.  
2.3 Results 




All cases of evolved high-level daptomycin resistance (HLDR) in C. striatum that were tested 
(Figure 2.1 and Supplemental Table 2.1) had a predicted loss of function mutation in PG synthase. 
We performed whole genome sequencing of eight pairs of in vivo and in vitro evolved HLDR C. 
striatum isolates (n = 16), and found pgsA2 to be the only gene mutated consistently in all HLDR 
mutants. The affected gene encodes PG synthase, responsible for converting CDP-DAG to PG 
(Figure 2.1A). The mutations observed include coding changes at universally conserved sites 
(Figure 2.1B), the dimer interface (Figure 2.1C), the active site (Figure 2.1D), and those leading 
to premature stop codons (Figure 2.1E). Each of these mutations is predicted by snpEFF (Cingolani 
et al., 2012a; Cingolani et al., 2012b) and PHYREII (Kelley et al., 2015; Kelley and Sternberg, 
2009) homology modeling to result in loss of PG synthase activity.  
We found no additional SNPs in the C. striatum genomes predicted to alter cellular biosynthetic 
processes in potential compensation for PG synthase loss of function. In B. subtilis, loss of just 
pgsA2 (PG synthase) was lethal and compensatory mutations were necessary for cell survival 
(Hachmann et al., 2011) leading us to consider whether additional mutations may also be required 
for HLDR in C. striatum. A total of 8 additional non-synonymous SNPs in biosynthetic pathways 
were detected in the in vivo evolved isolate (Supplemental Figure 2.1). Aside from the pgsA2 
mutation, no SNPs in biosynthetic pathways were detected in the in vitro evolved HLDR isolates. 
This is consistent with the longer time between susceptible and resistant isolate collection in vivo 
(17 days) versus in vitro (24 hours).  The remaining SNPs in genes not related to biosynthesis did 
not cluster in similar pathways (Raw data file, All SNPs tab). No consistent genetic change besides 
the loss of function mutation in pgsA is predicted to result in compensatory changes that would 





Each of the parent daptomycin susceptible C. striatum isolates were derived from different 
patients, and the in vivo and in vitro HLDR phenotypes were evolved independently (Supplemental 
Table 2.1). This breadth of evolution events in C. striatum isolates obtained from infected patients 
provides a robust, clinically relevant cohort for assessing mutations necessary to daptomycin 
resistance. Accordingly, comparative genomics indicates that loss of function SNPs in pgsA2 
encoding PG synthase are the only genomic change necessary for HLDR and no additional 
mutations are required to maintain resistant cell viability (Figure 2.1A-E). In a recent report of 
evolved xenobiotic resistance in Corynebacterineae (the suborder which includes 
Corynebacterium) minimal genetic mutations were observed between susceptible and resistant 
pairs, but large-scale transcriptomic changes were found to explain the change in phenotype (Hines 
et al., 2017; Yoneda et al., 2016). Accordingly, we tested whether whole cell transcriptional 
changes were potentially responsible for compensating the loss of PG synthase function and 
stabilization of the membrane in HLDR C. striatum.  
 
2.3.2 Minimal transcriptional changes in HLDR C. striatum 
No significant transcriptional changes were detected in biosynthetically linked genes in clinically 
evolved HLDR in C. striatum (Figure 2.2C, Supplemental Figure 2.2B and Raw Data: 
Transcriptomics). We compared the transcriptomes of the WP1a (index, daptomycin susceptible) 
and RP1b (HLDR evolved in the patient) strains grown in cation-adjusted Mueller-Hinton broth 
(CAMHB) to exponential phase in biological triplicate. Even the largest magnitude transcriptional 
changes did not exceed +/- 85%, much smaller than transcriptomic changes typically associated 




phospholipid biosynthesis were small in magnitude (less than 25%) and not significant (Figure 
2.2C and Supplemental Figure 2.2). Furthermore, most transcriptomic changes observed occurred 
in transposase genes and hypothetical proteins of viral origin. The most notable biosynthetically 
linked change was the LGFP repeat protein transcript detected at levels 1.302-fold (~30%) greater 
in the HLDR strain. PgsA2 expression levels changed by only 0.981-fold (not significant) in the 
HLDR strain, further indicating that the HLDR phenotypic consequence of the predicted PG 
synthase loss-of-function binding pocket mutation in the RP1b strain is due to loss of activity 
rather than expression. Lack of transcriptional alterations prompted us to interrogate the membrane 
composition of daptomycin susceptible and HLDR C. striatum strains using a comparative 
lipidomics approach. We hypothesized that the HLDR phenotype resulted from the disruption of 
PG synthase activity, which effectively removes PG from the membrane (Figure 2.2A).  
 
2.3.3 Lipidomics reveals loss of phosphatidylglycerol in the membrane 
We found that loss of PG synthase function leads to removal or at least a > 360-fold reduction of 
membrane phosphatidylglycerol (PG) content in HLDR C. striatum isolates. Analysis by mass 
spectrometry of whole-cell membrane lipid content of four pairs of daptomycin susceptible and 
HLDR isolates, which represent each of the four types of predicted loss-of-function pgsA2 
mutations (Figure 2.2 B-E and Supplemental Table 2.1) reveals loss of PG. In each isolate pair, 
PG detection was 369-1990-fold (p ≤ 0.0001) lower in the evolved HLDR isolates than in the 
daptomycin susceptible ancestor (Figure 2.3A), levels in the HLDR isolates which are indicative 
of complete removal of PG in the membrane, resulting in the HLDR phenotype. In addition to PG, 




C). However, CL was also absent in the daptomycin susceptible WP1a isolate, and because of 
subsequent in vitro data, we posit it is not the primary target of daptomycin. We also found no 
lipidomic evidence that the sn-1/sn-2 fatty acyl groups in PG is being modified to shield it from 
daptomycin binding hypothesized in low-level resistant S. aureus isolates (Ernst et al., 2009; 
Mishra and Bayer, 2013; Peschel and Collins, 2001; Staubitz et al., 2004). Conversion of PG to 
CL, a proposed mechanism of daptomycin resistance (Zhang et al., 2014b), also does not 
contribute to the C. striatum HLDR mechanism, since CL is absent in the HLDR strains (p ≤ 
0.0001) (Figure 2.3C). PG synthase converts CDP-Dag, a biosynthetic precursor of PG, into 
phosphatidyl glycerol (Figure 2.2A). In the absence of PG synthase, we expected CDP-Dag to 
either be utilized in a secondary lipid synthesis pathway or to accumulate in the cell. In support of 
the latter hypothesis, we found that CDP-Dag levels are significantly (543-5946-fold; p ≤ 0.0001) 
higher in HLDR isolates over their WT counterparts (Figure 2.2A and Figure 2.3B). PG synthase 
in HLDR strains across mutation types is nonfunctional (Figure 2.1B-E and Figure 2.2A) and no 
transcriptional compensatory changes are being made in the PG biosynthesis pathway (Figure 
2.2A-C, Supplemental Figure 2), enabling high-level CDP-Dag accumulation (Fig. 2a and Fig. 3).  
Until recently, determining the in vivo target of daptomycin had been challenging because it was 
biologically untenable to remove PG from the membrane of model Gram-positive bacteria without 
cell death (Garcia-de-la-Maria et al., 2013; Rubio et al., 2012). A recent study (Hines et al., 2017) 
corroborates that C. striatum appears to uniquely compensate for the complete removal of PG in 
its membrane by increasing the proportion of two other lipids in the membrane: PI (Figure 2.3E 
and Supplemental Figure 2.2A,B) and glucuronosyl diacylglycerol (Glua-Dag) (Figure 2.3D). PI 
is 1.6-5.3-fold higher (p ≤ 0.0001 and p ≤ 0.001) in HLDR over WT (Figure 2.3E and Supplemental 




(Figure 2.3D). We demonstrate that the previously proposed mechanisms of daptomycin resistance 
which include altering membrane fluidity, leaflet organization, and morphology do not contribute 
to HLDR in C. striatum, as the lipid membrane composition changes in the HLDR isolates do not 
visibly alter the membrane (by transmission electron microscopy, Supplemental Figure 2.4A) or 
charge (by zeta potential, Supplemental Figure 2.4B) compared to daptomycin susceptible 
counterparts. These data affirm that PG is the in vivo target of daptomycin and loss of PG due to 
non-functional PG-synthase is necessary and sufficient for the HLDR phenotype.  
 
2.3.4 Surface plasmon resonance indicates PG is the preferred target of daptomycin 
In support of our genomic and lipidomic conclusions, we performed a structure-function analysis 
of PG, which we show is the target of daptomycin and is necessary and sufficient for daptomycin 
activity in vitro. By combining Surface Plasmon Resonance (SPR), which measures binding. and 
carboxyfluorescein liposome stability assays (CFLSA) studies, which measure activity, we are 
able to understand the structural interactions of daptomycin with PG. We use 200 nm artificial 
liposomes of relevant membrane lipid compositions to determine these relationships. Four lipid 
species—PG, CL, phosphatidic acid (PA) and phosphatidylcholine (PC) (Supplemental Figure 2.3 
and Figure 2.4F)—were tested for daptomycin binding affinity. PI and Glua-Dag are both found 
in WT and HLDR isolates, and we did not test them in the next set of experiments because our 
lipidomics analysis indicated they are not the in vivo targets of daptomycin. Three types of 
liposomes of defined composition were assembled, comprised of PG, CL, and PA combined at a 
1:1 molar ratio with PC, and compared with homogeneous PC-only liposomes. Daptomycin 




other lipids tested (Figure 2.4). PG has been hypothesized to be an in vitro target of daptomycin 
due to its charged phosphate, however, the lack of binding to PC and minimal binding to PA 
(Figure 2.4E) indicate that the negatively charged phosphate plays a subordinate role in 
daptomycin binding. Additionally, when the fatty acyl groups are restricted to the bilayer surface 
plane, as they are in CL, daptomycin binds with much lower affinity (Figure 2.4A-E). When the 
phosphatidyl-sn-glycerol-3-phosphate glycerol head group is accessible, as it is with PG, the 
daptomycin binds more efficiently (Figure 2.4A-E). Also, the daptomycin binding to the 1:1 PG 
liposomes appears to saturate with daptomycin above 20 µg/ml indicating that PG is acting as a 
binding site for the daptomycin (Figure 4E). Accordingly, we would expect daptomycin activity 
to correlate with the binding of PG, CL, PA, and PC, and we tested this through a 
carboxyfluorescein liposome stability assay (CLFSA).   
 
2.3.5 CFLSA indicates PG is necessary and sufficient for daptomycin activity 
We found that presence of PG in the bacterial membrane correlates with daptomycin’s bactericidal 
activity. Carboxyfluorescein liposome stability assays (CLFSA) confirmed PG’s role in 
daptomycin activity in vitro. Liposomes were generated as above in the presence of self-quenching 
carboxyfluorescein. Daptomycin is added and interacts with the liposome membrane, releasing 
and diluting the carboxyfluorescein, which is then unquenched in the buffer producing 
dramatically increased fluorescence (Saito et al., 2000a). Daptomycin had higher activity against 
PG containing membranes in all cases (Figure 2.5A-F) and acts in a concentration dependent 
manner against both PG and PA (Figure 2.5F). Even though PA had lower binding affinity to 




liposomes containing CL where there are no available glycerol-3-phosphates extending from the 
membrane surface for daptomycin binding (Figure 2.5A, D). This is consistent with the observed 
PG to CL daptomycin activity relationship. Furthermore, this suggests to us that the larger (4 
alkane chain CL) suppresses daptomycin’s integration with membrane structure that is necessary 
for increased permeability in the CFLSA assay inhibiting daptomycin activity. We observed a 
reduction in daptomycin activity in liposomes that contain CL even though they have a higher 
binding affinity than PA and PC (Figure 2.4E and Figure 2.5A-F). These findings indicate that the 
conversion of PG to CL can reduce activity of daptomycin in membranes providing low-level 
resistance against daptomycin in vivo.  
 
2.3.6 CFLSA indicates PG concentration predicts daptomycin activity in vivo  
We found that daptomycin bactericidal activity is correlated with the percent composition of PG 
in the membrane. Liposomes with 0%-50% PG were generated as above and daptomycin’s activity 
against those liposomes were tested at a consistent 35 µg /ml daptomycin. At or above 20% PG 
composition, daptomycin did not show a significant change in activity (Figure 2.5G). This 
observation directly maps to daptomycin’s in vivo bactericidal activity as measured by MIC across 
a number of bacterial species. B. subtilis, C. striatum, and S. aureus strains with 30-50% membrane 
PG (Hachmann et al., 2011; McMullen et al., 2017b; Randall et al., 2013) content have MICs ≤ 1 
µg/ml daptomycin. Below 20% PG content, daptomycin’s activity drops precipitously, both in 
vitro and in vivo. Daptomycin resistant B. subtilis with a PG content of 10% showed a 27-fold 
increase in MIC (Hachmann et al., 2011). This is recapitulated with our artificial liposomes where 




fluorescence (Figure 2.5G), indicative of a loss in daptomycin activity. When membrane PG 
composition is ≤ 5%, daptomycin’s activity is indistinguishable from complete absence of PG in 
the artificial liposome. In HLDR C. striatum, which has 0% PG in its membrane we see a ≥4000 
increase in MIC (McElvania TeKippe et al., 2014; McMullen et al., 2017b) and our data shows a 
13.5-fold decrease in carboxyfluorescein fluorescence when the liposomes have < 5% PG. Thus, 
the percentage composition of PG relative to other membrane lipids is predictive of daptomycin 
susceptibility and activity both in vivo and in vitro. It also suggests that the CFLSA in vitro model 
is an effective method of studying daptomycin’s interactions with membranes.  
 
2.4 Conclusions 
C. striatum is an emerging, commensal opportunistic pathogen that has the potential to cause 
widespread harm in our hospital systems. The rapid adaptive evolution of loss of function pgsA2 
(PG synthase) mutations which result in the significant loss or removal of membrane PG are 
necessary and sufficient for high-level daptomycin resistance in C. striatum, which lead to 
catastrophic daptomycin treatment failure in patients. No additional genomic or transcriptomic 
compensation mechanisms are evident for the evolved HLDR phenotype. The HLDR mutants also 
have no changes in cell wall thickness, cell surface charge, conversion of PG to cardiolipin, or 
membrane shape, which are all mechanisms previously implicated in lower-level daptomycin 
resistance (Bayer et al., 2015; Bayer et al., 2016; Bayer et al., 2014; Bayer et al., 2013; D'Costa et 
al., 2012; Gaupp et al., 2015; Mishra et al., 2015; Mishra et al., 2009; Quinn et al., 2007; Raad et 
al., 2007; Reyes et al., 2015; Vanessa M. D’Costa, 2006; Zhang et al., 2014b). Rebalancing of 
membrane composition to include more PI in the absence of PG as observed by lipidomic profiling 




membrane, with simple loss-of-function point mutations in PG synthase, further demonstrates that 
PG is the in vivo and in vitro target of daptomycin. The remarkable ability of C. striatum to remove 
a previously presumed necessary membrane phospholipid could make C. striatum an ideal model 
for developing new Gram-positive antibiotics like daptomycin and studying the potential for 
resistance to develop.  
 
2.5 Methods 
2.5.1 Whole genome sequencing and comparison 
We sequenced 8 sets of C. striatum strains before and after emergence of high-level resistance to 
daptomycin. Isolates were sequenced using the Illumina Hi Seq 2500 platform, generating 101bp 
paired-end reads. One case of resistance emergence occurred in a patient bloodstream while the 
remaining strains evolved resistance during in vitro selection. We used the original susceptible 
patient isolate as our reference strain and assembled this genome de novo using SPADES 
(Bankevich et al., 2012). This reference genome was annotated using the Prokka v1.12 and the 
Pfam database. (Seemann, 2014) We assembled the remaining 15 genomes by mapping to this 
reference using bowtie2 (Langmead and Salzberg). We identified Single Nucleotide 
Polymorphisms (SNPs) between the resistant strains and their respective susceptible controls using 
Pilon. (Walker et al.) The effects of these mutations were predicted using SNPeff. (Cingolani et 
al.) All of the genes annotated in the reference genome were clustered by predicted metabolic 
function using Blast2Go(Conesa et al., 2005). Genes with predicted loss of function mutation were 
annotated on this metabolic map. pgsA2 was the only gene with biosynthetic function predicted to 
contain loss of function mutations in more than one case of HLDR (in fact, pgsA2 loss of function 




across all 8 strain pairs. Only 8 of these SNPs were in genes predicted to affect biosynthetic 
processes. After clustering by Gene Ontology (GO), pgsa2 altering phospholipid biosynthesis was 
the only metabolic alteration predicted in more than one case of resistance. Phyre2 homology 
modeling(Kelley et al., 2015)supported predictions that the pgsA2 mutation in every resistant 
strain was loss of function. 
2.5.2 Transcriptomic methods 
We performed transcriptomic profiling of the susceptible and the in vivo evolved resistant isolate 
from the original patient in triplicate. Frozen culture was streaked onto CAMHB plus blood plates 
and grown overnight for single colony selection and then and inoculated into 50 ml CAMHB broth 
and grown overnight. The following day, the cultures were diluted to 0.5 McFarland standard and 
split into three 100 ml cultures per condition. The diluted cultures were incubated at 37 °C with 
shaking for 1 hour. The cells were collected by centrifugation at 200 g for 15 minutes. The pellets 
were resuspended in RNAlater (76104 Qiagen) and frozen at -80 until analysis. 
We used bead beating and SDS treatment to disrupt the sample cells, phenol: chloroform extraction 
to remove proteins, and alcohol precipitation followed by DNAase treatment to isolate RNA from 
the frozen samples. Ribosomal RNA was removed with Ribo-Zero rRNA Removal Kit 
(Epicentre). cDNA libraries were generated from the isolated RNA and amplified as described in 
Yoneda, Henson et al., 2016. The double stranded cDNA libraries were sequenced using the 
Nextera (Baym et al., 2015) platform to generate at least 7 million 75bp reads from each sample.  
Reads from the triplicate susceptible and HLDR samples were aligned to the reference genome 
constructed from the index susceptible isolate using cufflinks. (Trapnell et al.) Differences in 




2013) Fold change was calculated as resistant expression level divided by susceptible expression 
level. Expression levels of the control housekeeping genes rpoA and gyrA remained constant in 
resistant versus susceptible samples (Fold change 1.02 and 1.00). Significance of changes was 
calculated using the beta negative binomial distribution previously described in Trapnell et 
al.(Trapnell et al., 2013) using a significance level of p < 0.05.  
2.5.3 Zeta potential measurement methods 
We performed surface charge measurement of the susceptible and HLDR resistant strains using 
zeta potential. (Kaisersberger Vincek et al., 2017) Frozen culture was streaked onto CAMHB plus 
blood plates and grown overnight for single colony selection and then and inoculated into 50 ml 
CAMHB broth and grown overnight. The following day, the cultures were diluted to 0.5 
McFarland standard and one 4 ml culture was grown per condition. The diluted cultures were 
incubated at 37 °C with shaking for 1 hour. One (1) ml of the culture was placed in a Malvern zeta-
sizing cuvette. Zeta potential (surface charge) was measured using a Zetasizer Nano ZS 
(ZEN3600) Dynamic Light Scattering System (Malvern Instruments) and compared between 
susceptible and HLDR paired strains. Expression levels of genes related to lipid biosynthesis are 
found in Figure 2 and Supplemental Figure 3. Additionally, genes with greatest fold changes are 
found in the Supplemental spreadsheet.  
2.5.4 Lipidomic methods 
We performed comparative lipidomics across all four mutation types. WT and HLDR matched 
isolates were grown overnight and diluted to an OD of 1 in 2.5 ml liquid culture in quintuplicate. 
Liquid cultures were spun down to the cell pellet and whole cell lipids were extracted using the 
Bligh-Dyer method (Bligh and Dyer, 1959). Samples were then stored at -20 until the lipids 




were normalized to 100 for each lipid with WT or HLDR being the normalizing lipid. The WT 
lipid was chosen as the normalizing lipid for PG, and Cardiolipin because they were most 
abundant in WT compared to the HLDR isolate. The HLDR lipid was chosen as the normalizing 
lipid for CDP-DAG, Glua-DAG and PI because they were most abundant in HLDR compared to 
the WT isolate. Statistical analysis was performed with 1-way anova and every column was means 
compared p £ 0.05 (*), p £ 0.01 (**), p £ 0.001 (***), p £ 0.0001 (****).  
2.5.5 Carboxyfluorescein liposome stability assay 
We performed a liposome disruption assay (Jimah et al., 2017) in triplicate to assess the activity 
of daptomycin on varying compositions of liposomes. Equimolar ratios of PG:PC, CL:PC and 
PA:PC with a PC only liposome control were created using the reverse phase method containing 
carboxyfluorescein (Szoka and Papahadjopoulos, 1978). Liposomes were then suspended in a 
buffer solution and subjected to varying concentrations of daptomycin from 3.125µg/ml-
1000µg/ml. Fluorescence increase due to daptomycin as a result of carboxyfluorescein release 
was measured using a Varian Eclipse Spectrophotometer with an excitation wavelength of 492 
and an emission wavelength of 512. Daptomycin activity was measured as a function of 
normalization to 100% release by triton x-100. Additionally, to assess PG% on daptomycin 
activity, PG:PC liposomes were created in triplicate with varying mole fraction ratios converted 
to PG% (50%, 40%, 20%, 15%, 10%, 5% and 0%) and subjected 35µg/ml daptomycin. Statistical 
analysis was performed with 1-way anova and every column was means compared p £ 0.05 (*), p £ 




2.5.6 Surface plasmon resonance 
We performed surface plasmon resonance(Kinouchi et al., 2013) in triplicate to assess the 
binding of daptomycin on varying compositions of liposomes. In equimolar ratios (1:1) of 
PG:PC, CL:PC and PA:PC with a PC only liposome control were created using the reverse phase 
method (Szoka and Papahadjopoulos, 1978). Liposomes were bound to carboxymethyl dextran 
hydrogel surface sensor chip that was treated with sphingosine and subjected to varying 
concentrations of daptomycin from 3.125µg/ml-35µg/ml. Baseline, stable liposome and peak 
daptomycin binding readings were collected. Daptomycin binding was normalized to liposome 
binding and presented as daptomycin/lipid unit. Statistical analysis was performed with 1-way 
anova and every column was means compared p £ 0.05 (*), p £ 0.01 (**), p £ 0.001 (***), p £ 












2.6 Main Text Figures 
Figure 2.1: All HLDR isolates have predicted nonfunctional mutations in pgsA2 
A, Structure of PG synthase monomer with mutations in conserved sites overlaid. B, mutation in 
CDP alcohol phosphatidyl transferase active site conserved across species. C, mutation in the 
dimer interface domain. D, mutation in substrate binding pocket. E, premature stop mutations 








Figure 2.2: Lipid metabolism pathway of Phosphatidylglycerol, observed SNPs and relative 
abundance changes of key lipids between WT and HLDR isolates  
The PG A, and CL B, lipid synthesis pathways were constructed with KEGG. 8 WT and HLDR 
isolate paired genomes were compared and nonsynonymous single nucleotide polymorphisms 
identified. The metabolites names and structures are on the left, with key lipids colored in red and 
green. R1 represents the 16:0 carbon chain and R2 represents the 18:1 carbon chain. The enzyme 




appropriate synthesis arrow. SNP mutations for each enzyme/gene unit are to the far right with the 
number of mutations out of the 8 HLDR isolates, unless no mutations were present in any of the 
isolates. Except for pgsA2, none of the lipid synthesis genes for PG have SNPS. On the left side, 
black bars indicate the functional completeness of the PG synthesis pathway. WT proceeds through 
the entire synthesis pathway producing PG, while HLDR ends at the production of CDP-DAG. 
The green color of the lipid CDP-Dag indicates a 543-5946-fold buildup of that metabolite in the 
HLDR isolates compared to WT. The Red color of PG and cardiolipin indicates a reduction of that 
metabolite in the HLDR isolates compared to WT with a 369-1990-fold reduction in PG. C, 
Expression levels of genes involved in lipid synthesis pathways were not significantly altered in 
HLDR (p>0.05). Expression levels of the housekeeping genes rpoA and gyrA were also not 









Figure 2.3: Lipidomic comparison of WT and resistant paired isolates across mutation types  
A-E The y-axis represents the relative abundance of the important phospholipid between the WT and 
HLDR isolates. WT-HLDR pairs are associated by color with WT represented by solid block colors 
and HLDR represented by black striped colors. The lipid that is most abundant in the WT or HLDR 
isolate has been normalized to 100. Fold changes, where calculable, are listed above the WT and 




‘a’ is the smallest to maintain a positive number. The structures of the lipid are directly to the right 
of the graph with R1 = 16:0 carbon chain and R2 = 18:1 carbon chain. Statistical analysis was 
performed with 1-way anova and every column was means compared p £ 0.05 (*), p £ 0.01 (**), p £ 

















Figure 2.4: Daptomycin binding across concentrations and liposome content  
A-E, The y-axis plots the normalized binding of daptomycin at varying concentration ratios to 
liposomes. The x-axis shows the type of liposomes tested, which include 1:1 equimolar ratios of PG, 
PA or CL to PC and a control liposome made entirely of PC. E, demonstrates stepwise increases in 
daptomycin binding to PG. F, structures of our lipid of interest. Statistical analysis was performed 
with 1-way anova and every column was means compared, p £ 0.05 (*), p £ 0.01 (**), p £ 0.001 








A-F, The y-axis plots the % activity of varying concentrations of daptomycin based on absolute 
fluorescence that is normalized to the fluorescence achieved by the addition of triton X-100. A-E, 
The x-axis shows the type of liposomes tested, which include 1:1 equimolar ratios of PG, PA, or CL 
to PC and a control liposome made entirely of PC. F, the x axis indicates the concentration of 
daptomycin added to the different liposome compositions. G, Relation of % activity of 35 µg/ml of 
daptomycin based on absolute fluorescence that is normalized to the fluorescence achieved by the 
addition of triton X-100 (y-axis) to the % PG content of the liposome tested with PC contributing the 
remainder of the required lipid to reach 100% composition (x-axis). Daptomycin activity against 
liposomes is correlated with MIC values for WT and daptomycin resistant bacterial isolates where 
the % PG content is known. Statistical analysis was performed with 1-way anova and every column 














2.7 Supplemental Figures 
Supplemental Table 2. 1: Available C. striatum isolates  
Isolate naming convention: W = WT, R = Resistant, P = Isolated from a patient, E = Evolved 
from a patient isolate in culture under daptomycin selection, # = Different isolate source, (a,b,c) 
= Isolate from same patient collected at different time points. All isolates’ genomes were 
sequenced. WP1a was used as the reference genome. All other genomes were mapped to this 
genome and SNPs found in the resistant and not the susceptible isolate from each pair were 
analyzed further. Transcriptomics was performed on WPIa and RP1b. Lipidomics was performed 





Supplemental Figure 2.1: Nonsynonymous mutations in biosynthetic pathways  
SNPs were clustered by functional category (using gene ontology). We found that pgsA2 was the 
only gene related to cellular biosynthetic function mutated with the exception of 8 additional 
mutations observed only in the in vivo evolved isolate. These mutations are consistent with the 
longer evolutionary time (17 days) experienced by the isolate between susceptible and resistant 









Supplemental Figure 2.2: Phosphatidylinositol lipid biosynthesis pathways  
The lipid synthesis pathways were constructed with KEGG. 8 WT and HLDR isolate paired 
genomes were compared and nonsynonymous single nucleotide polymorphisms identified. The 
metabolites names and structures are on the left, with key lipids colored in green. R1 represents 
the 16:0 carbon chain and R2 represents the 18:1 carbon chain. The enzyme nomenclature for each 
enzymatic step and their corresponding genes are located next to the appropriate synthesis arrow. 
SNP mutations for each enzyme/gene unit are to the far right with the number of mutations out of 




bars indicate the functional completeness of the PI synthesis pathway. WT and HLDR proceed 
through the entire synthesis pathway producing PI. The green color of the lipid PI indicates a 0.65-
4.25-fold buildup of that metabolite in the HLDR isolates compared to WT. Fold change was 






Supplemental Figure 2.3: Structures of the key phospholipids  
These lipids are critical to bacterial membrane composition. R1 = 16:0 carbon chain and R2 = 18:1 
carbon chain, black indicates the glycerol backbone, red indicates the phosphate group and green 





Supplemental Figure 2.4: Comparison of HLDR and WT lipid membranes and surface 
charge  
a, WP1a and RP1b isolates were imaged with transmission electron microscopy after 1 hour with or 
without the addition of 10µg/ml daptomycin. WP1a without daptomycin and RP1b with and without 
daptomycin show no membrane irregularities, while WP1a with daptomycin shows membrane 
blebbing and disruption. b, all available WT and HLDR isolate pairs were checked for surface 
membrane charge changes. Charge was not indicative of HLDR and the range of surface charge 
between the most and least negative WT and HLDR isolates were not significant, while there was 
significant variability in charge for both WT and HLDR when compared within MIC group.  
Statistical analysis was performed with 1-way anova and paired means analysis, p ³ 0.05 (ns), p £ 
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3.1 Abstract 
Daptomycin, a last line-of-defense antibiotic for treating Gram-positive infections, is experiencing 
clinical failure against important infectious agents.  While daptomycin has been studied for over 
30 years, conflicting proposed mechanisms of action have left two important questions 
unanswered; (1) how daptomycin interacts with the membrane of bacterial cells, and (2) how 
daptomycin causes cell death in bacteria.  The data reported here demonstrates a shift in how we 
understand the complexity of the interactions between daptomycin and the bacterial cell and aims 
to answer these two critical questions. We show that when daptomycin binds to the cell membrane, 
it is stably integrated into the membrane in a calcium- and phosphatidylglycerol (PG)-dependent 
manner, in a defined ~1:1 ratio of PG to daptomycin.  It then recruits or co-localizes with other 
daptomycin molecules to form stable pores with an approximate Stokes radius of 8 nm, resulting 
in an expulsion of metabolites, ions and other intracellular components from the cell.  When a high 
enough concentration of PG is present in bacterial membranes, enough daptomycin pores can be 








Daptomycin, an antibiotic discovered over thirty years ago, forms a last line-of-defense against 
deadly pathogens (Lakey and Lea, 1986). As a cyclic-lipopeptide, daptomycin belongs to a unique 
class of antibiotics and is backed by extensive research and testing efforts that led to approval for 
use in humans (Baltz, 2009; Taylor and Palmer, 2016). It has been used judiciously and serves an 
important role in treating antibiotic-resistant, Gram-positive bacterial infections. Although its 
mechanism of action has remained unclear, daptomycin targets the bacterial membrane, resulting 
in leakage of large molecules (determined using intracellular dyes) but not complete cell lysis 
(Cotroneo et al., 2008; Hobbs et al., 2008). Several mechanisms of action have been proposed, 
including pore formation (Zhang et al., 2014a), increased membrane permeability (Straus and 
Hancock, 2006), membrane deformation (Chen et al., 2014), division inhibition (Muller et al., 
2016) and peptidoglycan targeting (Allen et al., 1987). The first occurrences of clinical resistance 
to daptomycin in Staphylococcus aureus were incremental (Yang et al., 2013; Yang et al., 2010), 
and easily managed in patients through small daptomycin dose increases (Weis et al., 2008). The 
lack of resistance to high doses was ascribed to the target of daptomycin being the cell membrane 
(Alborn et al., 1991; Allen et al., 1991), with several in vitro studies identifying 
phosphatidylglycerol as its specific lipid target (Muraih et al., 2012). It was incorrectly assumed 
that bacteria would have difficulty making large scale shifts in membrane lipid composition 
(Hachmann et al., 2011; Hines et al., 2017), and thus would be unable to develop resistance. 
Corynebacterium striatum a Gram-positive opportunistic pathogen, has a unique ability to 
transition from being daptomycin susceptible (MIC = 0.064 µg/ml) to high level daptomycin 




well defined and is a biologically relevant pathogen, which allows us to employ it as an effective 
model for understanding daptomycin in vivo.  
In artificial membrane systems, daptomycin preferentially binds phosphatidylglycerol (PG) 
(Khatib et al., 2016; Kreutzberger et al., 2017; Taylor et al., 2017b; Taylor et al., 2016). The most 
likely proposed mechanism of action is that daptomycin forms 1:1 daptomycin:Ca2+ micelles (Jung 
et al., 2008; Jung et al., 2004; Scott et al., 2007), which dissociate in the presence of PG-containing 
membranes and then bind to the membrane via the hydrophobic 10-C acyl tail of daptomycin. 
Once bound, daptomycin integrates into the hydrophobic core of the bilayer (Jung et al., 2004; 
Lakey and Ptak, 1988[Jung, 2008 #8822) at a proposed ~1:1 ratio of PG to daptomycin (Lee et al., 
2017). However, determining the PG:daptomycin interaction stoichiometry has proven difficult, 
with various methods and lipid preparations yielding predicted stoichiometries ranging from 1:1 
in bicelles to 2:1 in liposomes (Zhang et al., 2013) (Muraih and Palmer, 2012). Beyond this point, 
it is unclear how daptomycin kills bacterial cells; however, there is substantial evidence in favor 
of membrane disruption, eventually resulting in cell death (Laganas et al., 2003; Mascio et al., 
2007; Pogliano et al., 2012; Silverman et al., 2003; Taylor et al., 2017a; Zhang et al., 
2014a,[Taylor, 2017 #9958). Previous elegant experiments have begun to dissect the binding and 
conformational changes observed in membrane-associated daptomycin (Jung et al., 2008; Jung et 
al., 2004; Lee et al., 2017).  
 
As recently as 2014, it was shown that daptomycin permeability was size- and cation-selective 
(Alborn et al., 1991; Allen et al., 1991; Zhang et al., 2014a). However, two shortcomings of these 




minimum inhibitory concentration (MIC) of 0.064 µg/mL and the peak reported serum 
concentrations of 100 µg/mL) of daptomycin (Antachopoulos et al., 2012; McElvania TeKippe et 
al., 2014), the mechanisms of membrane dysregulation were inconclusive. This could be 
potentially due to the different acyl tail type used in the model lipids for in vitro assays. Second, 
efforts to confirm ion leakage and pore formation in vivo using the Bacillus subtilis model (Muller 
et al., 2016) yielded results contrary to the proposed mechanisms identified in vitro.  Studying the 
mechanism of antibacterial action of daptomycin and other antimicrobial peptides will thus require 
a holistic approach, calling on genomics, transcriptomics, metabolomics and lipidomics, as well 
as classical biochemical and biophysical techniques.  
In this work, we address both outstanding issues regarding daptomycin’s mechanism; first, 
characterizing in vitro lipid:daptomycin interactions under physiologically relevant conditions, 
and then determining whether daptomycin is able to produce a pore of finite size and stable 
structure in both liposomes and bacterial cells themselves. We use planar lipid bilayers to 
differentiate the mechanism of action of daptomycin from that of valinomycin, an ionophore with 
a proposed mechanism similar to daptomycin. We employ a number of techniques that we first 
introduced in our studies of the Bax protein (Saito et al., 2000b) and the malaria protein CELTOS 
(Jimah et al., 2016) to identify and characterize the existence of a daptomycin-dependent pore. 
Surface plasmon resonance is used to directly quantitate daptomycin binding and subsequent 
integration into surface-supported liposomes, which allows us to directly measure the 
stoichiometry of the daptomycin-bilayer-PG interaction. We then extended these studies to 
measure the kinetics of daptomycin binding and release. Using large unilamellar vesicles (LUVs) 
of defined lipid composition, we first demonstrate that carboxyfluorescein is released by 




we use mass spectrometry to detect cellular components released from wild type Corynebacterium 
striatum by daptomycin treatment. 
3.3 Results 
3.3.1 Daptomycin disrupts membranes through a different mechanism than valinomycin. 
We first tested whether the mechanism of action of daptomycin can be explained solely by its 
interactions with the lipid bilayer. In order to determine how native daptomycin and lipid bilayers 
interact under physiological conditions, we turned to the planar lipid bilayer technique. We 
constructed planar lipid bilayers using a ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) to PG of 80:20, comparable to the ratio observed in susceptible bacteria (Hayami et al., 
1979). The salt concentrations on either side of the formed membrane were varied considerably, 
but we found that by having 145 mM NaCl and 5 mM KCl on each side of the membrane, we 
could directly compare valinomycin and daptomycin in the same salt solution. Triplicate trials 
were conducted using either daptomycin (0 to 64 µg/mL) or valinomycin (0 to 0.11 µg/mL). At 
sub-micromolar concentrations and at their respective minimal inhibitory concentrations (MICs) 
(3.4 µg/mL and 0.625 µg/mL for daptomycin and valinomycin respectively), both antibiotics 
reduced resistance by increasing membrane permeability and disrupting the required ion gradients 
of Na+ and K+ (Figure 3.1A). Removing the PG from membranes reduced daptomycin-induced 
permeability but had no effect on valinomycin. Plotting normalized membrane resistance 
(conductance-1) against antibiotic concentration also showed clearly different dose response curves 
(Figure 3.1B). Finally, we routinely observe large, voltage-dependent current spikes at slightly 
higher daptomycin concentrations (12.8 µg/mL) (Figure 3.1C). These current spikes are consistent 
with a pore or channel, and the magnitude of these spikes suggests that the observed pore or 




3.3.2 Daptomycin binds and stably integrates into PG-containing membranes. 
We employed surface plasmon resonance (SPR) to further define the daptomycin-PG interaction. 
Daptomycin preferentially bound to PG-containing membranes (Figure 3.2A and E) and remained 
stably integrated into the membrane for over 4 hours (Figure 3.2 – Supplement 1A). 
PG:phosphatidylcholine (PC)  liposomes retained 87.78% of total daptomycin at 10 minutes, and 
82.59% at 25 minutes, indicating that the daptomycin integrated into the membrane. Daptomycin 
bound cardiolipin (CL) membranes transiently but only minimally integrated into the membranes, 
with only 35.43% and 24.68% retention at 10 and 25 minutes respectively (Figure 3.2A and D). 
Daptomycin bound to phosphatidic acid (PA)-containing membranes transiently and to 
approximately the same magnitude as CL but was retained even more poorly, with only 11.55% 
remaining after 10 minutes.  The PC-only control liposomes showed the least initial binding and 
retention of all three lipids, with only 7.75% retention after 10 minutes, even in the presence of a 
negatively charged phosphate group (similar to PG). The stability of daptomycin in PG-containing 
membranes likely contributes to the non-lytic nature of daptomycin and makes the determination 
of the time of bacterial cell death problematic, since all measurements of cell death are taken 24 
hours later, after viability testing by growth plate (Murillo et al., 2009; Rybak et al., 2000).  We 
employed SPR to determine the ratio of PG:daptomycin to better understand the relationship 
between daptomycin activity, as quantified by MIC, and the PG composition of bacterial 
membranes.  
3.3.3 Daptomycin binds to PG at a 1:1 ratio.  
Using SPR, we determined the relationship between daptomycin and PG in order to understand 
the concentration-dependent nature of daptomycin activity (Batrakov and Bergelson, 1978; 




liposomes) which contain equimolar PG:PC and PA:PC lipid compositions were treated with 20 
or 35 µg/mL daptomycin. Using the signal change between the baseline and the liposome binding 
steady state, we were able to determine the signal specific to our lipids of interest (LOI: PG and 
PA) by multiplying by the mass fraction of 1:1 LOI:PC (Figure 3.3C). The LOI binding 
measurement was then plotted against daptomycin binding units and analyzed by linear regression, 
with the slope of the line corresponding to the daptomycin:LOI ratio. PG was found to bind 
daptomycin at a ~1:1 ratio (Figure 3.3A and D) while the PA to daptomycin binding ratio was 
~4.4:1, suggesting a significant decrease in the amount of daptomycin that can bind and integrate 
into PA-containing liposomes (Figure 3.2C). These data were corroborated by Lee et al., 2017, 
using small angle X-ray scattering to determine the daptomycin:PG stoichiometry (Lee et al., 
2017), indicating that SPR may be a valid method of determining antimicrobial peptide:lipid ratios 
in the future.  
3.3.4 Daptomycin binds and integrates rapidly into phosphatidylglycerol containing 
membranes. 
Daptomycin was injected at a fixed 35 µg/ml concentration over 1:20 PG:PC-containing liposomes 
for 15, 30 and 60 seconds. Daptomycin bound and integrated into the membrane in less than 15 
seconds, with mean retention of 78.14% after 10 minutes (Figure 3.4D and Figure 3.4 – 
Supplement 1). At 30 seconds, daptomycin binding had a slightly higher binding peak (Figure 
3.4A and C) than at 15 seconds, but after shedding unintegrated daptomycin, the mean retention 
of daptomycin was 75.85% at 10 minutes (Figure 3.4C, Figure 3.4 – Supplement 1), and was not 
statistically different from the 15 second injection, indicating the presence of a saturation point. 
The 60 second injection of daptomycin overwhelmed the liposomes; daptomycin bound the 1:20 




washed off the membrane, (Figure 3.4A, B and E) and liposomes showed 54.17% daptomycin 
retention at 10 min.  
3.3.5 Daptomycin forms pores large enough to be inhibited by 148.2 kDa dextran which has 
a Stokes radius of ~8 nm. 
Daptomycin forms pores at both 10 and 35 µg/mL (Figure 3.5A and B) in the presence of 20 µM 
dextran, ranging in size from 5-2000 kDa (66.9 kDa ~5.8 nm Stokes radius, 148.2 kDa ~8 nm 
Stokes radius, 500 kDa ~14.7 nm Stokes radius, and 2000 kDa ~27 nm Stokes radius) (Armstrong 
et al., 2004; Jimah et al., 2016; Saito et al., 2000b; Y Tang, 2016 ). At both 10 and 35 µg/mL, 
daptomycin pores were only blocked by 148.2 kDa dextran (Figure 3.5A and C) which resulted in 
56.3% and 41.4% reductions in carboxyfluorescein release, respectively (Figure 3.5D). The 
remaining dextran sizes were either too small or too large to block the pore, although there was a 
trend towards pore blockage as we increase the dextran size from 3 kDa to 148.2 kDa. The trenched 
nature of the fluorescence decrease is indicative of pore blockage, and the decrease independent 
of daptomycin concentration indicates that the pores are uniform in size (Stokes radius of ~8 nm) 
and may require a minimum amount of PG coupled to daptomycin to form.  
 
3.3.6 Daptomycin-treated C. striatum releases metabolites after treatment in a manner 
consistent with pore formation.   
C. striatum cultures were treated with daptomycin or vehicle control, and supernatants were 
collected at varying times thereafter. Analyzing these supernatants by mass spectrometry yielded 
relative intensities of 2960 molecular features present in at least one sample. Selecting only those 




alone, resulted in a final list of 111 features (Figure 3.6 – Supplement 1A). The distribution of 
feature intensities was strongly left-skewed, so intensities were log10-transformed to make them 
more normally distributed (Figure 3.6 – Supplement 1B and C).  
Independent Principal Component Analysis (IPCA) was utilized to identify features that differed 
in the supernatants from cells exposed to daptomycin compared to untreated cells. Using two 
principal components separated the treated and untreated culture supernatants at all five time points 
(Figure 3.6A). Of the 111 features used in the IPCA, 17 were assigned negative weights on 
principal component #1, suggesting that they were found in higher concentrations in supernatants 
from daptomycin-treated cells. Plotting these intensities over time showed this to be the case for 
many of the above features (Figure 3.6C). The masses of these features ranged from 188 to over 
600 Da, but the distribution of feature masses was not significantly different from the distribution 
of all feature masses detected in the experiment (Figure 3.6 – Supplement 1E) indicating that the 
method uniformly identified peaks in both the treated and untreated bacteria. The increase of 
feature appearance by principal component analysis in the daptomycin-treated cells suggests to us 
that a pore in the bacterial membrane could be the cause for feature release. However, these data 
prevent an estimation of an upper limit on the daptomycin pore size.  
 
3.4 Discussion 
The mechanistic details of the bactericidal action of daptomycin have remained vague due to 
conflicting reports, using multiple model systems that each have their own drawbacks. (Boudjemaa 
et al., 2016; Kreutzberger et al., 2017; Muller et al., 2016; Muraih and Palmer, 2012; Muraih et 




is directly related to its ability to make conformation shifts in its peptide core to interact with the 
cell membrane (Taylor et al., 2016; Zhang et al., 2014b). The simple substitution of Ca2+ to Mg2+ 
(or another divalent cation) (Ho et al., 2008), or removal of Ca2+ from solution is enough to increase 
the MIC of daptomycin from 1 µg/mL to > 32 µg/mL MIC (a > 32-fold increase) and the MIC of 
valinomycin from 0.625 µg/mL to > 64 ug/mL MIC (a > 102-fold increase) (Jung et al., 2004), 
showing that a single atom has the potential to drastically affect the activity of daptomycin in vivo. 
The addition of Bodipy, Alexa, or NBD to daptomycin  results in small molecule conjugation to 
daptomycin at points of interaction with bacterial cell membranes, which reduces its efficacy and 
potentially changes its target, which is reflected in its MIC (Taylor and Palmer, 2016); this 
increased MIC could be as a result of altering the ability of daptomycin to bind and integrate into 
membranes and later associate to form pores. Additionally, it is postulated that a lack in uniformity 
of the acyl chains of the LOIs—dimyristoyl lipids, palmitoleyl lipids, dioleyl lipids—contributes 
to these conflicting results (Taylor et al., 2017b). It is certainly possible that the acyl chain of 
daptomycin plays a role in efficacy as well; to address this, we used palmitoleyl lipids, 16:0-18:1, 
that represent the dominant acyl chain in wild type bacteria as well as daptomycin-susceptible 
Corynebacterium striatum, which is more biologically relevant. Based on studies to date, there are 
multiple and often conflicting proposed mechanism of how daptomycin interacts with the 
membrane and the cell. In this paper, we used clinically available daptomycin, and the SPR and 
carboxyfluorescein liposome stability assay (CFLSA) assays were performed on bacterially-
relevant size domain (200 nm) liposomes and wild type and daptomycin susceptible 
Corynebacterium striatum (MIC = 0.064 µg/ml), to ensure biological relevance (McElvania 
TeKippe et al., 2014). Some of these findings have been alluded to in previous publications; 




or PG has not yet been published. Furthermore, our data indicates that daptomycin kills susceptible 
bacteria by stably binding to membrane phosphatidylglycerol in a 1:1 ratio, integrating into the 
membrane to form large, stable, non-lytic pores, and releasing cytosolic metabolites and ions into 
the extracellular space.  
By starting our examination of daptomycin and valinomycin on planar lipid bilayers, we were able 
to directly observe membrane effects, in contrast to other methods that rely on indirect measures 
that may be subject to cellular interference. Previous work with ion-specific electrodes suggests 
that daptomycin at effective concentrations results in K+ loss, with depolarization occurring 
synchronously with cell death (Alborn et al., 1991; Allen et al., 1991). In membranes composed 
of phosphatidylcholine (PC) or PC-cholesterol mixtures, daptomycin increased permeability 
(Lakey and Lea, 1986), but the observed increase was judged insufficient to be toxic. Therefore, 
we decided to revisit the planar lipid bilayer experiments to determine if daptomycin has a 
sufficient effect on ion permeability to kill bacterial cells when presented with the right 
combination of lipids. The result is that while valinomycin is ion-specific, daptomycin appears to 
be ion-agnostic. At the center of the dose response curve, the fitted line has a slope that is 
proportional to the number of molecules that are required for transport across the membrane. 
Because the resistance is normalized, we cannot calculate the actual quantity of molecules 
required, but the slope for daptomycin is much larger than the slope for valinomycin, which 
corroborates daptomycin’s non-selective nature and hints at a larger pore structure than has 
previously been suggested.  
Daptomycin binding was originally cited as being potentially attracted to PG, based on the 
positively charged Ca2+ ion interacting with the acidic and negatively charged phosphate (Epand 




CL:PC and PC alone), focusing on the ability of daptomycin to integrate into the membrane after 
transient binding. The choline group in PC shields the phosphate from daptomycin and indicated 
that phosphate binding is secondary to the structure of the R-group atop the phosphate for initial 
binding and recruitment (Figure 3.2E). However, when the phosphate is unshielded (as in the PA 
liposomes) (Figure 3.2C) or has an amenable R-group (PG or CL liposomes) (Figure 3.2B and D), 
the phosphate plays an integral role in initial binding and recruitment of daptomycin to the 
membrane, but plays almost no role in the transition of daptomycin from its bound to integrated 
state (Figure 3.2A). The glycerol R-group of PG and CL has the structural characteristics that are 
optimal for daptomycin binding (Figure 3.2 – Supplement 1B). CL is unique here, in that it has the 
same R-groups as PG, but the glycerol is bound to another triacyl glycerol, such that the structure 
has a sequential triacyl glycerol – phosphate – glycerol – phosphate – triacyl glycerol (Figure 3.2 
– Supplement 1B). This fundamentally limits the movement of the glycerol R-group, such that 
when daptomycin binds, it cannot interact with PG in a way that allows for robust and rapid 
integration into the membrane. This leads to initial transient binding but limited long-term 
integration. It has been reported that CL inhibits the progression of daptomycin from the outer 
leaflet to inner leaflet of the membrane (Zhang et al., 2014b); in conjunction with our SPR data, 
this indicates that CL reduces the amount of daptomycin that can physically pack into the 
membrane to form a pore, which also increases the dissociation of daptomycin from the membrane. 
PG is unencumbered, which allows the glycerol R-group to conform appropriately to daptomycin 
and integrate into the membrane, indicating that both the phosphate and the glycerol groups are 
crucial for the binding and recruitment of daptomycin to the membrane, and the subsequent 
integration of daptomycin for pore formation (Figure 3.2A and B, and Figure 3.2 – Supplement 




Reduced PG content in the membranes of bacterial isolates has been associated with daptomycin 
resistance (increased MIC) (Hines et al., 2017) (Hachmann et al., 2011). Wild type C. striatum and 
Staphylococcus aureus have low daptomycin MICs, 0.032 – 0.125 µg/mL (McMullen et al., 2017a) 
and 0.064-0.38 µg/mL (Kaur et al., 2012) respectively, which can be in a large part due to the 
abundance of PG (~40%) (Hayami, 1979; Hines et al., 2017) in the membrane of each species. We 
used SPR to understand the relationship between PG and daptomycin and were able to elucidate 
that the stoichiometric ratio between the two is indeed ~1:1 (Figure 3.3A and D). Daptomycin 
activity is therefore constrained by the amount of PG present in the membrane. The result is that 
as membrane PG content decreases, daptomycin has a harder time locating PG and integrating into 
the membrane. To overcome the odds of locating a PG binding partner, more daptomycin is needed 
to ensure enough binding and membrane integration to form a pore (Hachmann et al., 2011). This 
hints at the possibility that there is a threshold amount of daptomycin that needs to be in the 
membrane to result in bacterial cell death; concentrations lower than this will allow bacteria to 
survive, suggesting that there is a minimum number of pores required for cell death.  
Daptomycin binding and subsequent integration or dissociation happens on the order of seconds 
(Figure 3.4D), so when daptomycin-susceptible C. striatum or S. aureus are exposed to 
daptomycin, the high PG content of both membranes allows daptomycin to locate, bind and 
integrate into the membrane extremely quickly. When PG is reduced from 4:10 lipids to 1:20 
lipids, we still see daptomycin binding very quickly when an overabundance of daptomycin is 
present (Figure 3.4). However, if we overload the system and oversaturate the PG content of the 
liposomes with daptomycin, almost all excess daptomycin dissociates (Figure 3.4B). When 
binding occurs but integration does not, as in the case with PA:PC liposomes, on average 81.5% 




combination of the 1:1 interaction, rapid binding and integration or dissociation helps explain why 
a reduction in PG results in an increased MIC.  
The planar lipid bilayer studies indicate that daptomycin forms a large pore that increases all ion 
permeability, not just potassium ion permeability. Potassium permeability was previously 
considered a mechanism of killing (Hobbs et al., 2008; Silverman et al., 2003; Zhang et al., 2014a) 
and while it still may contribute to cell death, it seems to be one of many factors. Using a 
carboxyfluorescein liposome stability assay coupled with dextran blocking, we were able to 
determine what daptomycin does after membrane integration (Jimah et al., 2016). If daptomycin 
formed an ion channel, very small pore, or no pore at all, then none of the dextran tested would 
block the pore. Our CFLSA studies indicate that daptomycin is forming a pore that is blocked by 
a 148.2 kDa dextran, with the same Stokes radius as the pore of ~8 nm across multiple daptomycin 
concentrations. This indicates that the pore size is stable and consistent across daptomycin doses 
(Figure 3.5). We further interrogated the pore by assessing mass of metabolites leaking through 
using C. striatum as an in vivo system.  
If daptomycin creates pores in model membranes, then it should behave similarly in bacterial 
membranes, causing intracellular metabolites to leak into the culture supernatant. Supernatants 
from C. striatum cultures treated with daptomycin were compared with supernatants from 
untreated cultures using liquid chromatography/time-of-flight (LC-TOF) mass spectrometry. As 
expected, this method detected daptomycin in all samples to which it was added (Figure 3.6 – 
Supplement 1D). To avoid ambiguity regarding the origin of the features, we selected only those 
features that were present in more than two samples and absent from media alone. IPCA analysis 
of the remaining features clearly separated treated from untreated supernatants (Figure 3.6A). 




untreated time points than the other daptomycin-treated supernatants, suggesting that the 
bactericidal effects of daptomycin manifest between 3 and 5 minutes post-treatment (Figure 3.6B). 
This was supported by the intensities of individual features identified by IPCA as associated with 
daptomycin treatment. The 4 most heavily-weighted features were all undetectable after 3 minutes 
in daptomycin, but increased substantially after 5 minutes, trends highly suggestive of metabolites 
leaking from daptomycin-treated cells (Figure 3.6C). In addition, several other features either 
began at high levels or peaked and then declined by 30 minutes post-daptomycin treatment. These 
trajectories are consistent with metabolites rapidly leaking out of cells and subsequently degrading. 
The masses of these features ranged from 188 to over 600 Da, suggesting that daptomycin-
generated pores are at least that large, but there is insufficient data to place an upper limit on the 
pore size (Figure 3.6 – Supplement 1E). Leakage of metabolites so shortly after the addition of 
daptomycin is consistent with rapid pore formation and recapitulates the in vitro data. Further work 
will be needed to characterize the structure and formation of the pore in vivo, and to establish an 
upper limit on the size of expelled metabolites. 
 
This data represents a shift in our understanding of how daptomycin interacts with the bacterial 
cell membrane, and how bacterial cell death results from daptomycin treatment. Once daptomycin 
binds to the membrane and integrates in a calcium- and PG-dependent manner, it is stably 
integrated. It then recruits or co-localizes with other daptomycin molecules to form stable pores 
with an approximate Stokes radius of 8 nm. The resulting pore allows metabolites, ions and other 
intracellular components to be released from the cell.  When sufficient PG is present in the bacterial 




3.5 Materials and Methods 
3.5.1 Planar lipid bilayer data collection and analysis 
Planar lipid bilayers were prepared by applying 40 µg of DOPC:PG or other lipids in n-decane to 
the 0.25 mm orifice of a polystyrene cuvette (Warner Instrument LLC, Hamden, CT). This orifice 
communicates between the cis and trans solutions of the bilayer chamber. These chambers were 
electrically connected by Ag/AgCl electrodes and 3 M KCl–3% agar bridges and currents 
monitored by a BCA-525-c bilayer clamp and headstage (Warner Instrument Corp.). The data were 
digitized using Axon software and a Digidata 1200 board (Axon Instruments, Foster City CA). 
Records were archived on video tape using a Neurocorder DR-484 (Neuro Data Instrument Corp., 
Water Town Gap, Hz). Data were filtered at 1000 Hz, and digitization was at 1.67x103 points/s. 
Analysis of the data was done using Axon, Excel and Origin software, OriginLab Corporation, 
MA. Prior to studies, membranes were allowed to thin to a capacitance of 400 nano-farads and had 
a leak current of ≤2 pA at 100 mV of applied potential. The daptomycin and valinomycin were 
added to the 1.0 mL cis chamber with stirring, and currents and voltages referenced to the trans 
chamber.  
3.5.2 Surface plasmon resonance data collection and analysis 
We performed surface plasmon resonance (Kinouchi et al., 2013) in triplicate on a Reichert 
SR7000 DC with an auto sampler, using a Carboxymethyl Dextran Hydrogel Surface Sensor Chip 
(#13206066). SPR Autolink Software version 1.1.8-0 was used to read and export data to 
Microsoft Excel. SPR was used to assess the stability of daptomycin binding, how daptomycin 
integrated into the membrane, rate of daptomycin integration into the membrane and ratio of 




used: PC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 16:0-18:1, Avanti Polar Lipids 
850457C), PG (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) 16:0-
18:1, Avanti Polar Lipids 840457C), PA (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (sodium 
salt) 16:0-18:1, Avanti Polar Lipids 840857C), and CL (1',3'-bis[1,2-dioleoyl-sn-glycero-3-
phospho]-sn-glycerol (sodium salt) 18:1, Avanti Polar Lipids 710335C). Stable daptomycin 
binding and integration was performed on equimolar ratios (1:1) of PG:PC, CL:PC and PA:PC 
with a PC-only liposome control. Daptomycin-to-lipid ratio was performed on equimolar ratios 
(1:1) of PG:PC and PA:PC liposomes. Rate of daptomycin binding and integration or dissociation 
was calculated with 1:20 PG:PC liposomes. All liposomes were created using the reverse phase 
method, 200 nm in size (Szoka and Papahadjopoulos, 1978), in the presence of elution buffer 
containing 100 mM KCl, 10 mM HEPES at pH 7.0, and 2 nM Ca2+. Liposomes were bound to a 
carboxymethyl dextran hydrogel surface sensor chip (#13206066) that was derivatized by treating 
the chip with a 1:1 mixture of 0.4 M EDC and 0.1 M NHS, then treated with 0.4 mM Sphingosine 
in DMSO. Reaction was quenched by 0.2 M Ethanolamine at pH 8.5. Bound liposomes were 
subjected to two concentrations of daptomycin (20 µg/mL and 35 µg/mL). Baseline, stable 
liposome and peak daptomycin binding readings were collected. Data was exported as a CSV and 
analyzed in Excel. 3 values are used during analysis to determine the daptomycin unit to lipid unit 
ratio: no lipid baseline, lipid peak, daptomycin peak. For daptomycin retention analysis, liposomes 
were completely loaded, and the plateaued value was aggregated and averaged up to the addition 
of daptomycin. The peak value of daptomycin was identified, and the range of values were 
aggregated and averaged. The delta of the peak daptomycin and lipid was divided by the delta of 
the daptomycin and lipid after the liposomes were washed with buffer (PG and CL at 25 minutes 




retention). For binding V integration analysis, the preceding 60 data points before daptomycin 
injection were examined for the lowest lipid unit value. The lowest lipid unit value was then 
subtracted from the daptomycin unit value to normalize and align all daptomycin peaks in triplicate 
and at the daptomycin injection time. All graphs and statistical significance were generated using 
a one-way ANOVA, and individual data columns compared for significance using the Tukey’s 
multiple comparisons test. XY data were analyzed by linear regression and the equation and slope 
with standard deviation are reported. p £ 0.05 (*), p £ 0.01 (**), p £ 0.001 (***), p £ 0.0001 (****). 
3.5.3 Carboxyfluorescein liposome stability assay data collection and analysis 
We performed a liposome disruption assay (Jimah et al., 2017) in triplicate to determine the size 
of the pore created by daptomycin in equimolar ratios of PG:PC liposomes. Liposomes were 
created using the reverse phase method containing carboxyfluorescein (Szoka and 
Papahadjopoulos, 1978) buffer, containing 100 mM KCl, 10 mM HEPES at pH 7.0, 2 nM Ca2+ 
and 10 mM carboxyfluorescein. Extrasomal carboxyfluorescein was removed from the liposomes 
using a G25 Sephadex sizing column with one volume of elution buffer. Liposomes were then 
suspended in a buffer solution in triplicate, containing 20 µM dextran at a size of 5 kDa, 9 kDa, 
39 kDa, 66.9 kDa, 148.2 kDa, 500 kDa, and 2000 kDa and subjected to two concentrations of 
daptomycin (10 µg/mL or 35 µg/mL). Fluorescence increase due to daptomycin as a result of 
carboxyfluorescein release was measured using a Varian Eclipse Spectrophotometer with an 
excitation wavelength of 492 nm and an emission wavelength of 512 nm. Daptomycin activity was 
measured as a function of normalization to 100% release by Triton X-100. Statistical analysis was 
generated using a one-way Anova and every column was means compared and multiple hypothesis 
corrected for significance using the Tukey’s multiple comparisons test. p £ 0.05 (*), p £ 0.01 (**), p 




3.5.4 In vivo daptomycin pore formation data collection and analysis  
Time course of daptomycin treatment 
Wild-type C. striatum was grown overnight at 37°C in cation-adjusted Mueller-Hinton Broth (CA-
MHB) and then diluted to an OD of 1.0 using fresh CA-MHB. 5 mL of this culture was then treated 
with 1 µL of 50 mg/mL daptomycin in water for a final concentration of 10 µg/mL. A control 
culture was grown in media without daptomycin and a blank was prepared by adding daptomycin 
to 5 mL of CA-MHB without cells. At 3, 5, 10, 15, and 30 minutes after daptomycin addition, 750 
µL of each culture was spun down at 3800×g for 6 minutes at 4°C. The supernatant was then 
removed and immediately frozen for storage at -20°C. 
Culture supernatant analysis by LC-QTOF 
A 100 µL aliquot of each culture supernatant was diluted in 300 µL MilliQ H2O and clarified using 
a 0.45 µm PVDF syringe filter. A 2 µL aliquot of each sample was then injected into an Agilent 
1290 Infinity UPHLC system fitted with a Waters Acquity UPLC HSS T3 column (2.1mm x 
150mm, 1.8 µm beads). Metabolites were separated using a linear gradient starting by holding 98% 
solvent A (0.1% formic acid in water) for 2 minutes. Solvent B (0.1% formic acid in acetonitrile) 
was increased to 98% in 9 minutes, held at 98% Solvent B for 6 minutes, and returned to 98% 
Solvent A over 1 minute. The column was allowed to re-equilibrate for 4 minutes between runs. 
Metabolites eluting from the UPLC were detected using an Agilent 6550 Jet Stream qTOF high 
resolution tandem mass spectrometer. The qTOF was set to 350 for sheath gas temperature, 12 
L/min for sheath gas flow, 250 for drying gas temperature, 11 L/min for drying gas flow, 35 psi 
for nebulizer pressure, and 3500 V for capillary voltage. The fragmentor voltage was set to 135 V. 




Sample chromatograms were aligned, and molecular features extracted using MassHunter 
Profinder and Mass Profiler Professional (Agilent). Features detected in the media blanks or 
present in ≤ 2 samples were discarded, leaving 111 features. Independent Principal Component 
Analysis (IPCA) was performed on the log10-transformed feature intensities using the mixOmics 


















Figure 3.1: Daptomycin disrupts membranes through a different mechanism than 
valinomycin.  
Planar lipid bilayers were constructed as described in Methods from DOPC:PG (80:20) or DOPC 
as indicated. (A) Valinomycin (in DMSO) or daptomycin (water) was diluted to the indicated 
concentration in 145 mM NaCl, 5 mM KCl and 10 mM HEPES at pH 7 (solution composition in 
both cis and trans chambers). Starting with no daptomycin or valinomycin present, a current-
voltage relationship was developed for each membrane by pulsing the membrane. Daptomycin 
was added with stirring and a minute allowed for complete mixing, with 2 mM CaCl2 present in 
the buffer. The conductance of each membrane was determined by pulsing at -80 to +80 mV (in 




concentration of daptomycin or valinomycin was tested in triplicate. The stable current in each 
pulse was used to averaged and used to construct a current-voltage profile for each membrane with 
valinomycin or daptomycin. (B) From the slope of each current voltage profile, the membrane 
resistance was calculated and normalized to 1 gigohm for native bilayer membranes. This is 
presented as a sigmoid fitted plot. (C) A complete I-V trial is shown with the record of voltage 
pulses on the bottom and the current response on top. The large rapid current pulses produced at 
constant voltage stimulus were seen when the daptomycin concentration exceeded ∼4.4 µM and 














Figure 3.2. Daptomycin stably binds and integrates into PG-containing membranes. (A) 
Percent retention of daptomycin to the 1:1 PG:PC, PA:PC, CL:PC and PC-only liposomes at 10 
and 25 minutes (PG and CL) or 10 minutes only (PC and PA) due to plateaued daptomycin 
retention. PG 10m (a) and PG 25m are not statistically different from each other and have the same 
statistically significant difference with CL 10m, CL 25m, PA 10m and PC 10m. Statistical analysis 
was performed with one-way Anova and every column was means compared using a Tukey HSD 
test with p £ 0.05 (*), p £ 0.01 (**), p£ 0.001 (***), p £ 0.0001 (****). Triplicate SPR tracings of 
daptomycin binding to artificial liposomes and release of daptomycin is observed over 10-25 
minutes (B) for PG (C) for PA (D) for CL (E) and for PC. PA and PC had only transient binding 
but no integration (C and E). PG and CL had sustained binding, but complete integration into the 









Figure 3.2 – Supplement 1: Long term daptomycin binding and lipid of interest structures. 
(A) Daptomycin binds PG stably over time. SPR tracings run in duplicate for 4.5 hours with 
daptomycin bound to equimolar PG:PC liposomes. Daptomycin retention at 4.5 hours is between 
60.3-64.1%. (B) Liposomes were made using PG, CL, PA and PC; the 16:0 18:1 R-group fatty 
acid tails are in blue, the glycerol backbone is in black, the phosphate is in red and the functional 









Figure 3.3: The phosphatidylglycerol to daptomycin stoichiometric ratio is ~1:1.  
20 and 35 µg/mL daptomycin was bound to equimolar (A) PG:PC (n=9) or (B) PA:PC (n=6) 
liposomes. Linear regression was applied to the data points and the equation and slope with 
standard deviation are reported. The slope of the line represents the lipid-to-daptomycin 
stoichiometry, (A) 1.01 for PG:daptomycin and (B) 0.2268 for daptomycin:PA or 4.41 for 
PA:daptomycin. (C) The arbitrary binding units for the LOI and daptomycin are normalized and 
each n is plotted on the XY graph (A, B). (D) The structure of daptomycin and PG in a 







Figure 3.4: Daptomycin binds and integrates into phosphatidylglycerol-containing 
membranes rapidly and can saturate membranes with low phosphatidylglycerol content.  
(A) 35 µg/mL daptomycin flowed over 1:20 PG:PC artificial liposomes in triplicate at injection 




and (C) 30s injections indicate similar binding and integration of daptomycin with the (B) 60s 
injections experiencing high transient binding of daptomycin, subsequent integration of 
daptomycin and a release of all non-integrated daptomycin. Statistical analysis was performed with 
one-way Anova and every triplicate tracing was means compared using a Tukey HSD test, with p £ 
0.05 (*), p £ 0.01 (**), p £ 0.001 (***), p £ 0.0001 (****). (B, E) At 5% PG, there is not adequate 
PG in the membrane for all available daptomycin to bind and maintain the ~1:1 binding ratio of 
PG to daptomycin, which results in nonintegrated daptomycin releasing from the membrane during 















Figure 3.4 – Supplement 1: Daptomycin retention after 15, 30 and 60 second injections.  
(A) Percent retention of daptomycin in 1:20 PG:PC liposomes after 60 seconds, 30 seconds and 
15 seconds. The 60 seconds injection saw a significant drop in retention, indicating saturation of 
daptomycin to PG and a rapid dissociation of daptomycin from the membrane. Statistical analysis 
was performed with one-way Anova and every triplicate point was means compared using a Tukey 












Figure 3.5: Daptomycin forms pores in PG-containing artificial membranes.  
Equimolar PG:PC liposomes were treated with daptomycin in the presence of various kDa dextran 
ranging in size from 5-2000 kDa in triplicate. (B) Daptomycin activity is time-dependent with a 
rapid release of carboxyfluorescein from the liposomes followed by a steady increase in 
florescence. Liposomes in 148.2 kDa dextran buffer treated with (A) 35 µg/mL or (C) 10 µg/mL 
of daptomycin saw a (D) 41%-56% decrease in normalized fluorescence, indicating that 148.2 kDa 
dextran blocks daptomycin pores. It also indicates that the size of the pore is consistent across 
daptomycin concentrations. Statistical analysis was performed with one-way Anova and means 




Figure 3.6: Mass spectrometry detects molecular features increased in culture supernatants 
by daptomycin treatment.  
(A) Plot of IPCA scores for untreated cell supernatants (white circles) and daptomycin-treated cell 
supernatants (black triangles). (B) Plot of IPCA scores on component #1 versus time, showing that 
the composition of the cell supernatants from treated and untreated cultures diverges sharply 
between 3 and 5 minutes post-treatment. (C) Plots of feature intensities versus time for each 
molecular feature assigned a negative weight in IPCA component #1. Features are sorted by 
weight, with the most strongly-weighted features in the top row. The neutral mass in Daltons and 




Figure 3.6 – Supplement 1: Treated and untreated supernatant features and distributions.  
(A) Frequencies with which each chemical feature was detected across all 15 samples. (B) 
Histogram of raw feature intensities showing that the distribution is extremely left-skewed. (C) 
Applying the log%&(𝑛 + 1) transformation to the intensities gives a histogram that is much closer 
to a normal distribution. (D) Intensity of the daptomycin signal in each culture supernatant. As 
expected, daptomycin was only detected in samples to which it was added. (E) Comparing the 
detection frequencies for all features (top) to the daptomycin-associated features alone (bottom) 
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Chapter 4: Conclusion 
This dissertation set out to answer four crucial questions about the biology of daptomycin. 
1) How do bacteria become hyper-resistant to daptomycin? 2) What is the in vivo membrane target 
of daptomycin? 3) How does daptomycin interact with the membrane? 4) What is daptomycin’s 
mechanism of killing? In our first paper (Chapter 2), we conclude that C. striatum, an emerging 
commensal opportunistic pathogen, develops high-level daptomycin resistance through the rapid 
adaptive evolution of loss-of-function pgsA2 (PG synthase) mutations. This mutation, in any 
variation that results in loss of function, results in the significant loss or removal of membrane PG, 
which is necessary and sufficient for high-level daptomycin resistance (HLDR) in C. striatum.  
HLDR leads to catastrophic daptomycin treatment failure in patients. No additional genomic or 
transcriptomic compensation mechanisms are evident for the evolved HLDR phenotype. The 
HLDR mutants also have no changes in cell wall thickness, cell surface charge, conversion of PG 
to cardiolipin, or membrane shape, which are all previously implicated mechanisms in lower-level 
daptomycin resistance. (Bayer et al., 2015; Bayer et al., 2016; Bayer et al., 2014; Bayer et al., 
2013; D'Costa et al., 2012; Gaupp et al., 2015; Mishra et al., 2015; Mishra et al., 2009; Quinn et 
al., 2007; Raad et al., 2007; Reyes et al., 2015; Vanessa M. D’Costa, 2006; Zhang et al., 2014) 
Rebalancing of membrane composition to include more PI in the absence of PG as observed by 
lipidomic profiling likely results in membrane stability. C. striatum’s ability to completely remove 
PG from its membrane, with simple loss-of-function point mutations in PG synthase, further 
demonstrates that PG is the in vivo and in vitro target of daptomycin.  These data give a clear 
identification of daptomycin’s in vivo membrane target, as well as the mechanism of high-level 




We were able to answer both these questions effectively; however, several mechanisms 
remained unclear. All of the evidence (genomic, transcriptomic and lipidomic) suggest that there 
is only one mutation, the loss-of-function mutation in pgsA2, that is essential; however, all attempts 
to knock the gene out have been unsuccessful, due in large part to C. striatum not being a model 
organism with robust genetic tools that would allow us to effectively manipulate its genome. Given 
the importance of C. striatum as a potential model organism for screening future lipopeptide 
antibiotics, new genetic tools should be developed to more intensely interrogate gene function. 
Additionally, while we were able to demonstrate that C. striatum can survive incredible shifts in 
membrane composition, it remains unclear how. Future experiments should focus on 
characterizing the metabolic activity of the proteins involved in the various lipid synthesis 
pathways of C. striatum. Specifically, it will be necessary to identify how Glua-Dag, CDP-DAG 
and PI metabolism shifts during the transition between WT to HLDR, as well as after HLDR is 
established. Finally, it is critical to understand whether the mutations that lead to HLDR are 
endemic in the population of C. striatum, or if HLDR is as a result of an unknown or 
uncharacterized stress response that randomly inserts these mutations into the genome. 
In our second paper (Chapter 3) we identify how daptomycin interacts with the membrane, 
and daptomycin’s mechanism of killing bacteria. Based on our data, we concluded that when 
daptomycin binds to the cell membrane, it stably integrates into the membrane in a calcium- and 
phosphatidylglycerol (PG)-dependent manner, at a defined ~1:1 ratio of PG to daptomycin.  It then 
recruits or colocalizes with other daptomycin molecules to form stable pores with an approximate 
Stokes radius of 8 nm. The resulting pore allows cytoplasmic metabolites, ions and other 




bacterial membranes, enough daptomycin pores can be formed to release biologically essential 
metabolites, ultimately killing the cell.  
Further work will be needed to characterize the structure and formation of the pore in vivo, 
establish an upper limit on the size of expelled metabolites, and determine how daptomycin co-
localizes for pore formation once it has integrated into the membrane. To characterize the structure 
of the pore, Cryo-EM, membrane NMR, or small angle x-ray diffraction could be employed. All 
three methods could be effectively carried out using in vitro model systems such as liposomes. 
Cryo-EM could determine the structure of pores using a more biologically relevant model, 
daptomycin-susceptible C. striatum. Establishing the structure of the pore would allow us to 
establish the size of the channel and unequivocally point to large pore formation as the mechanism 
of killing. Alternatively, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
could be employed to establish the upper limit of the size of metabolites or proteins leaking out of 
the pore, giving a biologically relevant determination of the size of biological material leaving the 
inside of the bacterial cell. One drawback of our original experiment looking at differential 
metabolite leakage was that it was optimized for small molecular weight metabolites, which 
prevent us from establishing the upper limit of the pore size. MALDI-TOF could address this issue. 
Finally, it is essential to understand how daptomycin forms pores once daptomycin molecules have 
bound and integrated into the membrane. The rapid nature of daptomycin activity in vitro makes 
this difficult to visualize or measure. One solution is to develop computational models that 
generate the membrane and daptomycin dynamics over a larger timescale. A drawback to this 
technique is the cost of computing power and the time necessary to render membrane dynamics, 
even on the nanosecond scale. Attempts to use fluorescent probes in vitro and in vivo to determine 




these probes often interferes with the activity of daptomycin, rendering the data uninformative or 
speculative at best. New techniques to study peptide-lipid interaction in membranes will be 
required to understand how daptomycin transitions from integration to pore formation without the 
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A1.1 Abstract 
Lignin-derived (e.g. phenolic) compounds can compromise the bioconversion of lignocellulosic 
biomass to fuels and chemicals due to their toxicity and recalcitrance. The lipid-accumulating 
bacterium Rhodococcus opacus PD630 has recently emerged as a promising microbial host for 
lignocellulose conversion to value-added products due to its natural ability to tolerate and utilize 
phenolics. To gain a better understanding of its phenolic tolerance and utilization mechanisms, we 
adaptively evolved R. opacus over 40 passages using phenol as its sole carbon source (up to 373% 




and 40. The two adapted strains showed higher phenol consumption rates (∼20 mg/l/h) and ∼2-
fold higher lipid production from phenol than the wild-type strain. Whole-genome sequencing and 
comparative transcriptomics identified highly-upregulated degradation pathways and putative 
transporters for phenol in both adapted strains, highlighting the important linkage between 
mechanisms of regulated phenol uptake, utilization, and evolved tolerance. Our study shows that 
the R. opacus mutants are likely to use their transporters to import phenol rather than export them, 
suggesting a new aromatic tolerance mechanism. The identified tolerance genes and pathways are 
promising candidates for future metabolic engineering in R. opacus for improved lignin 
conversion to lipid-based products. 
A1.2 Introduction  
Lignocellulosic biomass, comprised of cellulose, hemicellulose and lignin (1,2), remains an 
underutilized substrate in sustainable microbial production of fuels and chemicals (3–6). One main 
challenge is that current biorefinery pretreatment approaches release diverse toxic degradation 
compounds from lignin during conversion of lignocellulosic biomass to fermentable sugars (7). 
These lignin degradation compounds include a wide array of phenolics that can severely inhibit 
microbial production of fuels or chemicals, leading to lower yields (8). Currently, unconverted 
lignin is typically burned to provide thermal energy onsite, but the amount of waste lignin is 
predicted to escalate as lignocellulose-based biorefinery output increases (4,9,10). 
 
Lignin, the second most abundant terrestrial polymer, constitutes ∼15–30% of lignocellulose (11) 
and is more energy dense than cellulose and hemicellulose due to its higher carbon-to-oxygen 




structure. Structural heterogeneity also leads to a broad spectrum of breakdown products, 
substantially compromising the efficiency of chemical catalysis approaches for product synthesis 
and purification. Some bacteria and fungi can consume lignin breakdown products and utilize them 
as carbon sources (12), potentiating fuel and chemical production via lignin consolidated 
bioprocessing (13–15). One such bacterium, Rhodococcus opacus, is a promising microbial host 
for converting lignocellulose to useful products due to its naturally robust lipid production and 
ability to both tolerate and metabolize diverse phenolic compounds (14,16–18). 
 
Rhodococcus strains are found in diverse environments (19,20) and can tolerate environmental 
stresses such as desiccation and high salinity (21,22) as well as chemical stresses such as high 
concentrations of butanol (23,24). Often isolated from polluted or contaminated environmental 
samples (25,26), R. opacus strains have a strong innate tolerance to benzene, toluene and 
lignocellulosic hydrolysates from different sources (27,28) and can metabolize aromatic 
compounds (14,16). Rhodococcus species can convert aromatics to acetyl-CoA and succinyl-CoA 
(12,29), which are important precursors for converting phenolics to bioproducts (30). Originally 
isolated from soil at a gas works plant, R. opacus PD630 (hereafter R. opacus unless specified) is 
known to accumulate large amounts of the biodiesel precursors triacylglycerols (TAGs, up to 76% 
of cell dry weight) when using sugars as a carbon source. Thus, R. opacus has been a target strain 
for commercial-scale lipid production using sugars derived from lignocellulose (18,31–34). 
 
Growth inhibition by toxic compounds (either end-product or feedstock) is a major limiting factor 




tolerance to toxic inhibitors may significantly reduce time and efforts for host optimization. The 
tolerance capabilities of R. opacus are hypothesized to come from its highly hydrophobic cell wall 
(22) and/or its ability to consume a diverse array of compounds (20), but few studies have directly 
investigated phenolic tolerance mechanisms in this organism. While we have recently explored the 
central metabolism in wild-type (WT) R. opacus and found simultaneous utilization of glucose 
and phenol (i.e. no catabolite repression) using 13C-metabolite fingerprinting (37), more work is 
necessary to thoroughly characterize the catabolic pathways of aromatic compounds and global 
metabolism to elucidate tolerance mechanisms in R. opacus. 
 
In this study, we adaptively evolved increased phenol tolerance of R. opacus by sequentially sub-
culturing in phenol as a sole carbon source and screening fast-growing mutants over 40 passages. 
We selected phenol as a model lignin degradation product to avoid the confounding effects of 
many compounds present in heterogeneous lignin degradation product streams. Phenol has a 
shared substructure to many of the compounds that can be derived from lignin (38), and it also has 
a similar level of toxicity to that of other compounds derived from lignin (39,40). 
 
Even though previous studies have demonstrated bioconversion of lignocellulose-derived 
compounds into lipids by R. opacus (14,27,40–44), the connection between the tolerance 
phenotype and specific cellular mechanisms remains elusive. Here, we present a combined 
adaptive evolution/omics approach leveraging multiple phenol-adapted strains to identify possible 
mechanisms for phenolic tolerance and utilization in R. opacus (Supplemental Figure A1.1). This 




same strain background and resolving these tolerance strategies by comparing the transcriptomic 
response in different growth conditions. We performed adaptive evolution of R. opacus on 
increasing concentrations of phenol to select for increasingly tolerant strains and identified two 
high-performing strains through in-depth phenotyping. Next, we performed whole-genome 
sequencing of the selected strains to identify genomic alterations during adaptive evolution and 
employed comparative transcriptomics to identify transcriptional changes between strains in 
different growth conditions (i.e. in glucose and different concentrations of phenol). This approach 
proved to be effective in gaining insights into tolerance mechanisms and identifying promising 
gene candidates that can facilitate future metabolic engineering efforts in Rhodococcus to produce 
fuels and chemicals directly from lignin breakdown products or from lignocellulosic hydrolysates 
rich in toxic lignin degradation compounds. 
A1.3 Materials and Methods 
A1.3.1 Adaptive evolution  
To increase the strain's tolerance to phenol, R. opacus PD630 was adapted to grow in increasing 
concentrations of phenol for 40 successive subcultures. To start the experiment, the WT strain was 
grown in 2 ml of 0.3 g/l phenol for 2 days, and then subcultured at 0.3 g/l phenol with an initial 
OD600 of 0.03 during the first 10 subcultures. Once the culture reached an OD600 of 0.3 within 
24–36 h, the phenol concentration was increased in increments of 0.25 g/l up to a final 
concentration of 1.5 g/l phenol. Frozen stocks of each subculture were saved for later testing. To 
pick phenol-tolerant strains, frozen stocks from intermediate subcultures were streaked onto 
minimal media plates supplemented with 1.5% agar containing 0.3 g/l phenol. From three of the 




for growth screening and lipid assays in 96 well plates. The two fastest growing strains with best 
lipid productivities (named evol33 and evol40) were chosen from this screening for further 
analysis.  
A1.3.2 Lipid assay 
The two best performing strains were chosen for lipid assays using Nile red. Growth experiments 
were started with single colonies from LB plates, and cells were cultured in 2 ml of 0.3 g/l phenol 
in a 50 ml glass tube for 36–48 h. Next, 2 ml of cells was subcultured in 10 ml of 0.3 g/l phenol 
for 24 h in a 50 ml glass tube. Next, 10 ml of cells was added to 140 ml of 0.3 g/l phenol in a 250 
ml flask and grown for 24 h. Cells were centrifuged at 3000 x g for 10 min, resuspended in carbon- 
and nitrogen-free media, and then each condition (1 g/l glucose, 0.75 g/l phenol or 1.5 g/l phenol) 
was tested for each strain with an initial OD600 = 0.3 in low nitrogen conditions (0.05 g/l 
(NH4)2SO4) at a 10 ml volume in a 50 ml glass culture tube. Cells were stained by Nile red 
according to the reported method (45) with some modifications. Briefly, 200 µl of cell culture was 
stored in 20% DMSO at −20°C until staining. For staining, cells were centrifuged at 1000 x g and 
room temperature for 3 min and resuspended in 200 µl of 1x PBS. 5 µl of 1 mM Nile red in DMSO 
was added to each sample in a 96-well plate, which was subsequently incubated in the dark at 
room temperature for 30 min. The plate was wrapped in foil, centrifuged at 1000 x g for 3 min and 
washed twice with 0.9% NaCl solution. Flow cytometry analysis was performed using a Millipore 
Guava EasyCyte High Throughput flow cytometer with a 488 nm excitation laser and a 575 nm 
emission filter. For all data, at least 5000 events were collected and gated by forward and side 
scatter. Samples were stained and analyzed on the same day to decrease variability. FlowJo 
(TreeStar Inc.) was used to obtain the arithmetic mean of the Nile red fluorescence distributions 




value. Because of differences in lag phases between strains, the lipid productivity was calculated 
as the average change in Nile red fluorescence (per cell per time) between at least four time points 
taken from the exponential to the stationary phase. 
A1.3.3 Illumina library preparation 
A protocol adapted from Bowman et al. and Fisher et al. (46,47) was used to generate Illumina 
sequencing libraries. Double-stranded cDNA (for RNA-Seq) or genomic DNA (for whole genome 
sequencing) in 50 µl elution buffer (Qiagen) was fragmented to 200–400 bp using Covaris E-220 
and microTUBEs at a recommended setting by Covaris. ∼50 µl of fragmented DNA in Buffer EB 
(Qiagen) was recovered from Covaris tubes and transferred to a semi-skirted 96-well polymerase 
chain reaction (PCR) plate. 20 µl of end repair mix (7 µl 10x T4 ligase buffer, 2.8 µl 10 mM 
dNTPs, 3.5 µl T4 polymerase, 3.5 µl T4 polynucleotide kinase, 0.7 µl Escherichia coli DNA 
polymerase I and 2.5 µl nuclease-free water; all enzymes were purchased from NEB) was added 
to the fragmented DNA to blunt and phosphorylate the ends at room temperature for 30 min. 130 
µl of AMPure XP beads (Agencourt) were added to each well to remove reagents from the previous 
step. The 96-well plate was placed on a magnetic plate after pipetting thoroughly to mix, and 
supernatant was discarded when it became clear. The beads with DNA on the walls of 96 wells 
were washed with 150 µl 80% ethanol once, before eluting the DNA with 32 µl of water. 18 µl of 
dA-tailing mix (5 µl 10x NEBuffer 2, 1 mM dATP and 3 µl Klenow fragment (3′-5′ exo-)) was 
added to the beads with eluted DNA to add a dA-tail at 37ºC for 30 min. After dA-tailing, 110 µl 
of 20% polyethylene glycol (PEG) 8000 in 2.5 M NaCl was used to precipitate DNA onto the 
magnetic beads. The plate was placed on a magnet again to collect DNA and washed with 80% 
ethanol. Barcoded adapters were added to the eluted DNA (20.5 µl water added to DNA with 




temperature for 20 min. 21 µl of 20% PEG in 2.5 M NaCl was added to precipitate DNA onto the 
beads, and two barcoded samples were pooled after washing for elution. Adapter-ligated DNA was 
then PCR-amplified using KAPA HiFi Hot start Readymix (KAPA Biosystems) and gel purified 
using a Zymoclean Gel DNA Recovery Kit (Zymo Research). The resulting purified DNA samples 
were quantified using a Qubit DNA HS kit, combined and diluted with Buffer EB to yield a 10 
nM pool. 20 µl of the pool was submitted to HiSeq-2500 sequencing at the Center for Genome 
Sciences & Systems Biology, Washington University in St. Louis School of Medicine. For other 
details regarding DNA and RNA preparations, see Supplemental Materials and Methods.A1.3.4 
A1.3.4 Genome sequencing and SNP analysis 
Raw Illumina reads were demultiplexed by barcodes and trimmed using an in-house Python script, 
and mapped to an indexed genome of R. opacus (both annotated supercontigs maintained by Broad 
Institute (Genbank#ABRH01000000 (20)) and the finished genome by Chinese Academy of 
Science (ASM59954v1 (48)) using Bowtie2 (49). The mapped SAM files were converted to sorted 
BAM files with BAM index files using SAMtools (50,51). SNPs and possible indels were analyzed 
using Pilon (52). SNPs that were also found in the WT strain were filtered out using an in-house 
Python script (see Supplemental Computational Methods). Additionally, MIRA (53) was used to 
confirm SNPs and indels predicted by Pilon. In addition to utilizing MIRA's SNP detection 
function, we performed de novo-assembly of a genome for each strain using MIRA. Assembled 
genomes were then used to further confirm presence or absence of SNPs in each strain. This deep 
sequencing confirmation eliminated SNPs that were inconsistently found due to Illumina 
sequencing errors or biases during Illumina preparations. Table Table1A1A shows all SNPs found 
in evolved strains and not in WT. 




After demultiplexing and trimming, raw Illumina reads were mapped to an indexed genome of R. 
opacus (both annotated supercontigs (20) and the finished genome (48)) using Bowtie2 (49). The 
mapped SAM files were converted to sorted BAM files with BAM index files using SAMtools 
(50,51). FeatureCounts (54) was used to count the number of reads per coding sequence, and the 
raw result was used for differential expression analysis using DESeq2 (55) as implemented in the 
R software package. 
A1.4 Results 
A1.4.1 Adaptive evolution of R. opacus PD630 using phenol as a sole carbon source  
In the adaptive evolution approach, we increased phenol concentrations in a minimal salts medium 
(MSM) over time to select for the fastest growing strains using phenol as a sole carbon source 
(Supplemental Figure S1). Growth of the WT strain on phenol was characterized by a lag phase 
that increases with higher concentrations of phenol (Figure A1). To prevent long lag phases in 
adapted strains, cells were grown in non-inhibitory concentrations of phenol for the initial rounds 
of selection before increasing to inhibitory phenol concentrations. Serial transfers were performed 
when exponential phase was reached (optical density at 600 nm (OD600) of ∼0.3). For the total 
adaptive evolution experiment (40 serial passages), the estimated cumulative cell divisions (56) 
were ∼6 × 109, assuming four doublings per subculture and an initial cell concentration of ∼1 × 
107 CFU/ml (colony forming unit per ml; initial OD600 of ∼0.03 was experimentally determined 
to be ∼1 × 107 CFU/ml). Over the course of the 40 serial transfers (∼200 generations), six colonies 
each from passages 17, 26, 33 and 40 (total of 24 colonies) were randomly selected for high-
throughput phenotypic screening, along with WT (Supplemental Figure A1.1). We chose the two 




yields: one derived from passage 33 (named evol33) and the other from passage 40 (evol40). These 
two adapted strains were subjected to further phenotypic characterization (i.e. growth profiles and 
lipid accumulation assay), deep whole-genome sequencing and comparative transcriptomic 
profiling by RNA-Seq. 
A1.4.2 Phenotypic characterization of phenol-adapted strains 
To characterize improvements in tolerance from adaptive evolution, both adapted and WT strains 
were cultivated in a range of concentrations of phenol (Figure A1.1). We characterized phenol 
tolerance by comparing growth rates, final biomass accumulation (OD600), lag phases and 
estimated IC50 (half maximal inhibitory concentration; Supplemental Figure A1.2). The adapted 
strains evol33 and evol40 had 20% and 24% higher IC50 values than WT, respectively, after 45 h 
of culture (P < 0.001 for both evol33 and evol40, one mean, two-tailed Student's t-test). Both 
adapted strains also reached 22–373% higher cell densities (P < 0.05) than WT in all 
concentrations of phenol tested where growth was observed (0.75–2 g/l), with evol33 and evol40 
having a 92% and 102% increase in OD600 at 1.5 g/l (P = 0.0005 and P = 0.0002, respectively; 
Supplemental Table A1.1). The lag phase of the adapted strains was 17–54% shorter compared to 
that of the WT strain, with evol33 showing a 46% shorter lag phase at 1.5 g/l (P = 0.029) and 
evol40 showing a 34% shorter lag phase compared to WT (P = 0.054; Supplemental Table A1.2). 
The adapted strains also demonstrated significant growth rate increases at intermediate 
concentrations of phenol, with 30% and 38% increases in growth rates at 1.5 g/l for evol33 (P = 
0.03) and evol40 (P = 0.04), respectively (Supplemental Table A1.3). When cells were grown in 
1.5 g/l phenol, we also observed significantly higher phenol consumption rates in the adapted 
strains compared to the WT strain (P = 0.002 and P = 0.003 for evol33 and evol40, respectively), 





To determine whether adaptive evolution affected lipid accumulation, we measured lipid amounts 
under nitrogen-limited conditions using either glucose or phenol as a sole carbon source (Figure 
A1.2 and Supplemental Table A1.4). WT R. opacus accumulates intracellular lipids in the form of 
TAGs under nitrogen limitation in the stationary phase (18). Strains were grown in 1 g/l glucose 
(‘glucose’), 0.75 g/l phenol (‘low phenol’) or 1.5 g/l phenol (‘high phenol’) as sole carbon sources. 
Relative lipid amounts at different time points were estimated by staining cells with Nile red and 
measuring single cell fluorescence, which has been used to characterize total lipid contents in many 
oleaginous organisms (15,45) and correlates well with total lipid content (Supplemental Figure 
A1.4). Peak lipid accumulation occurs in the mid-stationary phase, followed by a decrease in lipid 
contents due to lipid consumption caused by extended carbon starvation. Because cells would be 
harvested at peak lipid accumulation for an industrial-scale process, we used the maximum Nile 
red fluorescence in the stationary phase to compare the lipid titer (Supplemental Table A1.4) 
between strains. The adapted strains showed similar maximum Nile red fluorescence to that of the 
WT strain when grown in glucose (P = 0.1 and P = 0.09 for evol33 and evol40, respectively). In 
contrast, when grown in low phenol, evol33 and evol40 showed a 2.5-fold (P = 5 × 10−5) and 1.9-
fold (P = 0.001) increase in maximum Nile red fluorescence compared to WT, respectively 
(Supplemental Table A1.4). The adapted strains also showed high lipid accumulation in high 
phenol (Supplemental Table A1.4 and Supplemental Figure A1.5). In addition to titer, productivity 
is also an important factor for industrial scale processes, and we compared lipid productivity 
between strains by examining the average increase in Nile red fluorescence over time in 
exponential to stationary phase (Figure A1.2, Supplemental Table A1.5, and Supplemental Figure 




three strains showed similar lipid productivities ranging from 7.8 to 8.4 arbitrary unit (a.u.) h−1. 
While the WT strain demonstrated a lower lipid productivity in low phenol (5.8 a.u. h−1), the 
adapted strains showed similar or higher lipid productivities in low phenol compared to glucose 
conditions (13.6 and 8.9 a.u. h−1 for evol33 and evol40, respectively). Compared to the WT strain, 
evol33 and evol40 has a 2.3- and 1.5-fold increase in lipid productivity in low phenol. The adapted 
strains also had higher lipid productivity in high phenol compared to glucose conditions (16.5 a.u. 
h−1, P = 0.001 for evol33; and 19.4 a.u. h−1, P = 0.0001 for evol40). These results prompted us 
to further characterize these strains using whole-genome sequencing and RNA-Seq. 
A1.4.3 Deep whole-genome sequencing of phenol-adapted strains 
We sequenced the genomes of phenol-adapted R. opacus strains evol33 and evol40 along with the 
original wild-type strain to > 90X-coverage. For a reference genome, we used both annotated 
supercontigs maintained by the Broad Institute (Genbank # ABRH01000000 (20); OPAG_#s) and 
the finished genome by the Chinese Academy of Science (ASM59954v1 (48); LPD#s). Contrary 
to our initial expectations, there were no single nucleotide polymorphisms (SNPs) or 
insertion/deletions (indels) in promoter regions, transcriptional regulators, or sensors. In fact, the 
numbers of mutations were low, and when excluding mutations that were found in WT as well, 
there were only three consistent mutations (which were not due to sequencing errors) in evol40 
and four mutations in evol33. While we explored the possibility of large duplications as genomes 
of Rhodococcus species are known to contain duplications (57–59), we could not obtain consistent 
large duplication prediction based on short read sequencing only. The three common point 
mutations shared in the genomes of both evol33 and evol40 (Table A1.1A) are the following: 
LPD03112, annotated as ‘cytochrome c oxidase/cytochrome aa3 quinol oxidase’, contained a Phe 




protein/citrate transporter/MFS transporter’, contained an Ile296 to Phe mutation. The third shared 
mutation occurred in OPAG_05248, which is annotated as ‘acyl-CoA thioesterase II’, and had a 
silent mutation of G to A (Phe120) when mapped to the supercontigs (20). When mapped to the 
complete genome (48), however, this mutation occurred in an intergenic region between 
LPD04711 and LPD04712 (Table A1.1A). Regardless of the annotations, overall reads mapped to 
this region were very low (reads per kilobase of transcript per million reads (rpkm) 0–10) and not 
phenol-responsive (Table A1.1B,C),suggesting caution when considering the biological 
implication of this mutation. evol33 additionally had a gene LPD00118 with a SNP; this gene is 
annotated as ‘4-hydroxyphenylacetate permease/MFS transporter’ (Gly162 to Val). Given two 
transporter/permease genes containing consistently found SNPs, these results suggest that adapted 
strains have altered transport of phenol or related compounds. 
A1.4.4 Transcriptomic analysis of phenol-adapted strains 
A1.4.4.1 Stress adaptation in evol33 and evol40 compared to WT 
To investigate tolerance mechanisms further, we employed a comparative transcriptomic approach 
by sequencing ribosomal RNA-depleted total RNA from WT, evol33 and evol40 in the three 
medium conditions described in Materials and Methods. High phenol (1.5 g/l) was used for 
adapted strains only, since the wild-type strain did not reach adequate cell densities at this culture 
condition. High phenol condition data were used to assess whether the up- or downregulation of 
genes was phenol concentration-dependent. Three biological replicates of each strain and 
condition showed consistent gene expression results (Figure A1.3 and Supplemental Figure A1.7; 
in Figure A1.3, each square on a heat map represents a biological replicate). In addition to coping 




promote lipid accumulation), cells came in contact with phenol, which is generally toxic to cell 
membranes and cellular macromolecules (60,61). As expected, multiple putative stress genes were 
upregulated due to nitrogen-limited growth conditions and the toxicity of phenol. Some of the 
annotated stress genes that were upregulated in all strains in phenol growth conditions were ‘DNA 
protection during starvation protein’ LPD04106, ‘heat shock protein 20 homolog’ LPD07748 and 
‘molecular chaperone DnaK’ LPD02079 (Table A1.2 and Supplemental Table A1.6, Sheet 13). 
LPD04106 was highly expressed in glucose, but even more upregulated in low phenol in WT and 
evol40 (Table A1.2 and Supplemental Table A1.6). evol33 showed modest upregulation of 
LPD04106 (2.64-fold) in low phenol. In adapted strains in high phenol, expression levels of 
LPD04106 were similar to that of glucose (no change in evol33 and 1.3-fold downregulation in 
evol40). LPD07748 was highly upregulated in low phenol in all strains, but to a less extent in 
adapted strains in high phenol compared to low phenol (Table A1.2 and Supplemental Table A1.6). 
LPD02079 was 16-fold upregulated in WT in phenol, while it was 3.1- to 6.3- fold upregulated in 
adapted strains in phenol (Table A1.2 and Supplemental Table A1.6). These results suggest that 
adapted strains show less stress response to phenol-containing media than WT. 
A1.4.4.2 Phenol degradation and utilization genes were highly upregulated in adapted strains 
Genes that were more than 1024-fold upregulated in phenol compared to glucose across all strains 
were LPD06575 and LPD06576, which are annotated as ‘flavin-dependent monooxygenase, 
reductase subunit/phenol monooxygenase reductase’ and ‘4-hydroxyphenylacetate 3-
monooxygenase’, respectively. In addition to these two genes, LPD06740, LPD06741 and 
LPD06742 were also more than ∼1000-fold upregulated in phenol in evol33 and evol40  (Figure 
A1.3, Table A1.2, and Supplemental Figure A1.8). LPD06740 and LPD06741 have high identity 




LPD06742 is annotated as catechol 1,2-dioxygenase (Figures A1.3 and A1.4). WT did upregulate 
the LPD06740 operon in phenol, but the expression levels were 3- to 18-fold lower than that of 
the adapted strains (Figure A1.3, Table A1.2, and Supplemental Figure A1.8). 
LPD06575/LPD06740 and LPD6576/LPD06741 are likely to be small and large components of 
two-component phenol hydroxylase, where LPD06575/LPD06740 are flavin reductases and 
LPD6576/LPD06741 are NADH-dependent phenol hydroxylases, as there are reports of 
biochemically proven two-component phenol hydroxylases in other Rhodococcus species (62,63). 
Gene duplication of this region is also documented, and R. opacus strain 1CP is thought to have a 
third copy of the genes (59). Based on our transcriptional data, R. opacus appears to utilize both 
copies of the two-component phenol hydroxylase genes, but the adapted strains have the ability to 
upregulate the second copy (phenol degradation cluster #2; Figures A1.3 and A1.4B) more than 
the WT strain. Notably, the second copy of the phenol hydroxylase genes is directly upstream of 
a catechol 1,2-dioxygenase gene (Figure A1.4B), which is the first gene in the catechol branch of 
the β-ketoadipate pathway (Figure A1.4A; 12). Both copies were tightly regulated by the presence 
of phenol, and AraC-family transcriptional regulators are found in the same operons (Figures A1.3 
and A1.4B). Moreover, other downstream genes in the β-ketoadipate pathway, such as 
muconolactone delta isomerase and muconate cycloisomerase, are upregulated more in the adapted 
strains, especially in high phenol (∼2000-fold; Figures A1.3 and A1.4A), and they are located in 
the same operon as IclR-family regulators (LPD05454, LPD06569 and LPD06698; Figures A1.3 
and A1.4A). We searched for genomic mutations near differentially regulated operons such as the 
phenol degradation cluster #2, but the closest SNP observed was over 2 Mbp upstream of 




could be affected by an indirect cause, such as intracellular concentrations of regulatory molecules 
or metabolites. 
RNA-Seq also revealed that R. opacus upregulates the gentisate pathway of aromatic degradation 
and utilization when phenol concentration was elevated to 1.5 g/l, while predicted meta-cleavage 
aromatic degradation pathway genes and anaerobic aromatic degradation genes did not seem 
utilized (Supplemental Figures A1.9 and A1.10). These results strongly suggest that adapted 
strains efficiently detoxify phenol mainly via the ortho-cleavage pathway and utilize it as a carbon 
source through the β-ketoadipate pathway (12). 
 
There are over 380 genes annotated as transcriptional regulators or regulatory proteins in R. 
opacus. Of those, ten genes are annotated as ‘probable thc operon regulatory protein’ (AraC-family 
transcriptional regulator). Of the ten genes, LPD06577, LPD06739 and potentially LPD06574 are 
putative regulators of the highly phenol-responsive phenol degradation genes based on the 
proximity of the genes to phenol degradation genes and expression profiles (Figure A1.3). A gene 
annotated as ‘xylose repressor’ (LPD06565) may be involved in regulating the β-ketoadipate 
pathway cluster #2 because it is co-regulated with the genes in the cluster. β-ketoadipate pathway 
operons seem to be associated with genes annotated as Pca regulon regulatory protein (IclR family 
transcriptional regulator; LPD05454, LPD06569 and LPD06698). Although the gentisate pathway 
operon was adjacent to an AraC-family transcriptional regulator (LPD03777), their expression 
patterns were not similar (Supplemental Figure A1.9). However, their expression patterns were 
similar to an annotated serine/threonine-protein kinase gene (LPD03770) downstream of the 





Genes most downregulated by phenol in WT were LPD02697 (NDMA-dependent methanol 
dehydrogenase/lactaldehyde reductase; >6500-fold downregulated) and two hypothetical protein 
genes downstream of LPD02697 (Table A1.2 and Supplemental Table A1.6, Sheet 14). Adapted 
strains did not show dramatic downregulation of this gene in low phenol, but did show strong 
downregulation in high phenol (Table A1.2 and Supplemental Table A1.6, Sheets 15-18). A 
homolog of LPD02697 is implicated in oligotrophic growth of Rhodococcus erythropolis N9T-4 
(64). In all strains, methane monooxygenase component genes were among the most 
downregulated in phenol conditions. 
When comparing the low phenol and glucose conditions in terms of global regulatory changes, 
evol33 had higher average levels of upregulation from fewer genes than WT and evol40, and both 
adapted strains had fewer downregulated genes than WT, which were also generally 
downregulated to a lesser extent than WT (Supplemental Tables A1.6 and A1.7 and Supplemental 
Figure A1.11). 
A1.4.4.3 Upregulation of transporter genes in phenol 
While genomic data suggested that phenol transport could be altered in the adapted strains, it did 
not give a complete picture about how the adapted strains could tolerate and utilize higher 
concentrations of phenol compared to WT. Significant expression differences were not observed 
between WT and adapted strains in transporter genes identified to have SNPs by whole-genome 
sequencing. However, a few other putative transporter genes were observed to have altered 
expression levels (Table A1.2 and Supplemental Table A1.6). We identified a highly upregulated 




compared to 5-fold in WT in low phenol, and upregulated to higher degrees in high phenol in 
adapted strains), which is annotated as a shikimate transporter gene (LPD06699). Shikimate is a 
cyclohexene compound that is a precursor for aromatic amino acids, and it contains functional 
groups similar to many phenolic compounds derived from lignin (65). LPD07505, also annotated 
as a shikimate transporter, was 3.2-fold downregulated in WT in low phenol, but was upregulated 
in both low and high phenol in adapted strains, especially in evol33 (8.5-fold compared to glucose 
in high phenol; Table A1.2 and Supplemental Table A1.6). No other genes annotated as shikimate 
transporters showed similar upregulation patterns, and shikimate utilization genes were not 
upregulated in phenol (Supplemental Table A1.6, Sheet 12). Moreover, phenol was more quickly 
consumed by the adapted strains than WT (Supplemental Figure A1.3), suggesting that increased 
phenol uptake may play a role in phenol tolerance and utilization in R. opacus. 
A1.4.4.4 Lipid biosynthesis and metabolism genes were differentially regulated in adapted 
strains. 
R. opacus TadA is a heparin-binding hemagglutinin-like protein required for normal lipid droplet 
morphology, which is thought to colocalize with lipid droplets (48,66). Interestingly, the gene 
encoding TadA (LPD06283 (48,66)) was upregulated in phenol in all strains (Supplemental Table 
A1.6, Sheet 13; >24-fold in WT and >27-fold in evol33). This finding prompted us to speculate 
that lipid droplet morphology may be different in R. opacus strains depending on the carbon 
source. However, there was no marked change in size or number of lipid droplets when comparing 
cells in glucose to cells in phenol (Supplemental Figure A1.12). LPD05549, annotated as a fatty 
acid synthesis gene (FASI), was upregulated 33- to 64-fold in all strains in phenol compared to 
glucose. 8 out of the 11 genes annotated as stearoyl-CoA 9-desaturase or stearoyl-CoA 9-




whereas 24 of the 45 genes annotated as fatty acid –CoA ligase were greater than 2-fold 
downregulated in phenol in WT (19/45 genes in evol33 and 22/45 genes in evol40 were >2-fold 
upregulated), although the degree of fold change differed significantly between WT and adapted 
strains (representative genes shown in Table A1.2 and Supplemental Table A1.6, Sheet 13). 
A1.4.4.5 Effects of nitrogen limitation on R. opacus transcriptome 
In glucose, strain-to-strain variation in global expression was low (Supplemental Figures A1.7 and 
A1.13), and the most highly expressed genes assessed by DESeq2 were LPD00472 (porin protein), 
LPD04147 (linear gramicidin synthase subunit C/non-ribosomal peptide synthase), LPD03031 
(nitrite extrusion protein) and LPD03032 (nitrite reductase; Supplemental Table S6). LPD00472 
was a highly abundant transcript and was slightly downregulated (up to 4-fold) in phenol growth 
conditions, probably reflecting the hydrophobic nature of phenol compared to hydrophilic glucose. 
Normalized counts using plotCounts function of DESeq2 comparing these genes, phenol 
degradation genes and constitutively highly expressed housekeeping genes (such as DNA-
dependent RNA polymerase subunits (LPD06131/6132), ClpX (LPD05487), and elongation factor 
Tu (LPD06091)) are shown in Table A1.2. Because we used a minimal salts medium with a 
reduced nitrogen concentration, we expected that genes involved in nitrogen limitation would be 
highly expressed. This speculation was confirmed by the extremely high expression of LPD03031 
and LPD03032 (Table A1.2). In fact, some of the most highly expressed genes across all strains in 
all medium conditions included proteasome genes LPD04933 (Mpa homolog/ATPase) and 
LPD04928 (proteasome endopeptidase complex beta subunit). As shown in R. erythropolis (67), 
R. opacus is likely equipped with a complete set of components to constitute active proteasomes, 




carbon source (glucose or phenol) did not seem to affect proteasome gene expression (Table A1.2; 
less than 2-fold up- or downregulated). 
A1.5 Discussion 
In this work, we analyzed genomic and transcriptomic changes between adaptively evolved R. 
opacus mutants and the WT strain grown in phenol. Laboratory adaptive evolution has been used 
for many different bacteria to improve growth on diverse compounds (68). We used phenol as a 
sole carbon source in our adaptive evolution process and identified strains with higher tolerance 
to the toxic chemical by measuring their total biomass accumulation, lag phase and growth rate 
(Figure A1.1 and Supplemental Tables A1.1–A1.3). After ∼200 generations, adapted strains 
contained 3–4 SNPs in the genomes, which was more rapid accumulation of SNPs than reported 
by Lenski et al. in their long-term evolution experiment and other labs (8.9 × 10−11 per base-pair 
per generation; 69). Strong selective pressure by the toxic compound being the sole carbon source 
probably contributed to the faster rate of SNP accumulation compared to the E. coli experiment, 
although the ‘normal’ rate of SNP accumulation during adaptive evolution in R. opacus has not 
been determined. Unfortunately, we did not identify ‘obvious’ SNPs that contributed to the striking 
transcriptomic profile difference between WT and evolved strains. The two adapted strains had 
improved growth profiles with increased biomass accumulation and shorter lag phases that could 
be due to altered transport of phenol in the mutants, leading to changes in intracellular 
concentrations of phenol and thus expression of phenol-responsive genes for phenol detoxification 
and degradation. 
Differences were also observed between WT and adapted strains in terms of lipid accumulation. 




succinyl-CoA via the β-ketoadipate pathway (12). Acetyl-CoA can be integrated directly into fatty 
acid biosynthesis pathways, and succinyl-CoA can enter the TCA cycle to generate reducing 
equivalents and ATP for cell growth and lipid synthesis (70). Compared to WT, the adapted strains 
maintained the ability to synthesize and accumulate lipids when grown in glucose, but they both 
accumulated significantly more lipids than WT when grown in phenol (Figure A1.2, Supplemental 
Tables A1.4 and A1.5). 
The adapted strains in this study demonstrated high phenol consumption capabilities that match or 
surpass other phenol-degrading bacterial strains and mixed cultures. Pseudomonas putida 
MTCC1194, which was adapted for growth in phenol as a sole carbon source, had maximum 
phenol degradation rates of ∼12 mg phenol/l/h during growth at its maximum phenol concentration 
of 1 g/l (71). Another approach used mixed cultures to increase phenol degradation capacity, with 
tolerances up to 0.8 g/l phenol and degradation rates of 15.4 mg/l/h (72). Another approach is to 
isolate strains directly from environments such as contaminated wastewater. Bacillus brevis, 
isolated from an industrial wastewater, showed the highest phenol tolerance and utilization at 
concentrations up to 1.75 g/l phenol with degradation rates of ∼20 mg/l/h (73). Our adapted strains 
showed higher tolerance than B. brevis with growth in 2 g/l phenol, and experiments at 1.5 g/l 
showed phenol degradation rates of 22 and 21 mg/l/h for evol33 and evol40, respectively 
(Supplemental Figure A1.3). In summary, evol33 and evol40 demonstrated comparative phenol 
degradation rates and tolerances to the best-performing environmental isolates. 
Our transcriptomic data suggested that phenol-adapted strains express lower levels of stress-
response genes in the conditions tested (low nitrogen, minimal media and phenol as a sole carbon 
source). Phenol is known to cause oxidative stress response in bacteria (74). In our study, R. opacus 




be involved in oxidative stress resistance (75,76). It seems likely that low nutrient condition can 
induce the gene, but the adapted strain, especially evol33, showed significantly lower upregulation 
of this gene compared to WT in phenol, suggesting that evolved strains sensed less oxidative stress 
in our experiment. A similar trend was observed with the major housekeeping chaperone genes. 
DnaK is a major bacterial Hsp70 (70 kDa heat shock protein) and functions with co-chaperones 
GrpE and DnaJ to prevent aggregation of denatured proteins (77,78). R. opacus expressed 2 copies 
of the dnaK operons (LPD2079–02081 and LPD03845–03847) in the conditions we tested, and 
the major operon appeared to be LPD02079 and the following 3 genes. All DnaK and co-chaperone 
genes were upregulated more in WT than in the phenol-adapted strains in low phenol, indicating 
that the low-nutrient, phenol medium condition encountered by WT may cause proteins to misfold, 
and that the phenol-adapted strains encounter lower level of cellular stress than WT at the same 
concentration of phenol in the media. 
 
We observed clear patterns of altered gene regulation in phenol-adapted strains compared to WT 
R. opacus in response to phenol. In WT, one of the two copies of phenol hydroxylase genes was 
dominantly upregulated, but in adapted strains the second copy (LPD06740 and LPD06741) was 
also upregulated to the same or even higher level (Figure A1.3, Table A1.2 and Supplemental 
Figure A1.8). Both SNP analysis and RNA-Seq results suggest that transport of phenol or 
compounds related to its metabolism is altered in the adapted strains. In fact, phenol was consumed 
at faster rates by the adapted strains than the WT strain (Supplemental Figure A1.3). evol33, which 
additionally had a putative transporter gene with a single point mutation compared to evol40 
(Table A1.1), upregulated phenol degradation genes more strongly than evol40 (Figure A1.3). It 




catabolism are AraC/XylS family (79–81). AraC/XylS-family transcriptional regulators bind to 
ligands (e.g. arabinose), and upregulation of effector genes is tunable by adjusting the 
concentration of ligands (82–84). Therefore, it is possible that adapted strains allow more phenol 
molecules to be transported into the cell, which in turn activate the second phenol degradation 
operons to the degree observed (6307-fold upregulation in evol33, 2624-fold upregulation in evo40 
and 657-fold upregulation in WT; Figure A1.3 and Supplemental Table A1.6). Higher upregulation 
of β-ketoadipate pathway genes in adapted strains could also be influenced by higher intracellular 
concentrations of phenol or its downstream metabolite, catechol, which has been observed with 
aromatic degradation pathways in other organisms (79,80). 
 
There are 46 genes annotated as shikimate transporters in the complete genome of R. opacus. Of 
the 46, LPD06699 was uniquely co-upregulated with phenol degradation genes, at 353- and 103-
fold in evol33 and evol40 comparing low phenol to glucose, and 937- and 572-fold in evol33 and 
evol40 comparing high phenol to glucose, respectively. In WT, LPD06699 was upregulated 5-fold 
in low phenol compared to glucose. Except for LPD07505, which was upregulated in phenol only 
in adapted strains, none of the other genes annotated as a shikimate transporter were regulated in 
the same manner (Supplemental Table A1.6). Furthermore, predicted shikimate utilization genes 
LPD05461, LPD06023, LPD17011 and LPD05485 were not highly transcribed or upregulated in 
phenol (Supplemental Table A1.6), suggesting that LPD06699 and potentially LPD07505 may be 





Another interesting finding was the upregulation of a putative YRNA and Rsr (85) in adapted 
strains in phenol. YRNAs were recently found to exist in a wide variety of bacterial species, 
including R. opacus (86). R. opacus Rsr homolog, LPD06269, caught our attention because of its 
phenol-responsive upregulation in evolved strains, even though it was annotated as a hypothetical 
protein. LPD06269 was constitutively expressed at a medium-low level in all strains in glucose 
but upregulated 52-fold in low phenol compared to glucose and 115-fold in high phenol compared 
to glucose in evol33 (8.3-fold and 17-fold in evol40), and upregulation of the predicted YRNA 
region showed the same pattern (Supplemental Figure A1.14). In WT, transcript levels of 
LPD06269 slightly decreased in low phenol (0.87-fold), and no upregulation of YRNA region was 
observed, suggesting that this response was phenol-dependent and specific to the adapted strains. 
We are in a process of focusing on small noncoding RNAs in R. opacus, since we removed the 
majority of small RNAs from the total RNA samples in order to obtain maximal amount of mRNA 
in this study. Nonetheless, our results indicate that small RNA-mediated global response may also 
be involved in adaptive evolution of R. opacus against phenol as a sole carbon source, and it may 
explain the ability of R. opacus to rapidly adapt to diverse environments without accumulating 
substantial genomic changes. 
 
This work suggests that characterizing funneling pathways (which convert lignin-derived 
compounds into pathway metabolites such as catechol; 87) and transporters for phenolics is 
important for conversion of phenolics into fuels and chemicals. Genes converting phenol to 
catechol were some of the most highly upregulated genes when strains were grown in phenol 
compared to glucose, suggesting that phenol-to-catechol conversion may be a limiting step for 




condition), phenol seems to be degraded mainly by ortho-cleavage via the catechol branch of the 
β-ketoadipate pathway into succinyl-CoA and acetyl-CoA, consistent with our previous result 
obtained from WT cultures grown in 0.5 g/l phenol supplemented with 13C glucose (37). Other 
phenolic compounds would require other funneling enzymes to convert them into precursors such 
as catechol and protocatechuic acid for degradation (87). This study also identified putative 
transporters for phenol, and transport of many different phenolic compounds would require either 
promiscuity for transporters or different transporters for each compound. Note that while previous 
studies on transporters of toxic chemicals focused on efflux pumps to minimize the intracellular 
concentrations of these compounds (88–90), R. opacus is likely to use its transporters to import 
toxic phenolics, suggesting a new mechanism of bacterial aromatic tolerance. Increased phenolic 
compound flux into the cell requires balancing between transport and degradation to prevent 
accumulation of toxic compounds within the cell. 
 
A recent study demonstrated that adaptive evolution can increase R. opacus tolerance to 
lignocellulose-derived inhibitors (40). While they used media supplemented with glucose, our 
evolution process is different in that phenol was used as a sole carbon source to obtain highly 
tolerant mutants to phenol. Consequently, we were able to decouple the effects of other potentially 
available carbon sources in lignocellulose-derived feedstock on changes in the genome and 
transcriptome. We also demonstrated that phenol as a sole carbon source can support R. opacus 
for both growth and accumulation of lipids (biodiesel precursors) and that adaptive evolution can 
increase lipid productivity, an important factor for current lignin conversion processes (15). 




tolerance mechanism of the promising production host, facilitating future lignocellulose, 











A1.6 Tables and Figures 
 
Table A1: Single nucleotide polymorphisms (SNPs) found in the adapted strains.  
(A) All SNPs found in the adapted strains but not in the WT strain are summarized. The mutations 
were called by both Pilon and MIRA. (B) Expression levels of the genes listed in A, shown in 
DESeq2-normalized counts, using plotCounts function. (C) Expression levels of the same genes 
listed in A, in Reads per Kilobase of transcript per Million mapped reads (rpkm). Rpkm values are 
calculated as explained in the Materials and Method section, and the average of triplicate samples 





Table A1.2: Summarized fold changes of selected genes.  
WT LowP, WT in low phenol versus glucose; evol33 LowP, evol33 in low phenol versus glucose; 
evol33 HighP, evol33 in high phenol versus glucose; evol40 LowP, evol40 in low phenol versus 
glucose; evol40 HighP, evol40 in high phenol versus glucose. For DESeq2-normalized count data, 
counts are shown in each condition specified, rather than comparing to glucose (Glc, 1 g/l glucose; 




function of DESeq2 and averaging triplicate samples. More information of this chart can be found 




















Figure A1.1: Growth comparison between the two phenol-adapted strains and the WT strain 
in diverse growth conditions.  
The adapted strains and the WT strain were grown in multiple concentrations of phenol as their 
sole carbon source to characterize improvements in tolerance after adaptive evolution (phenol 
concentrations as indicated; 1 g/l ammonium sulfate). The adapted strains grew to higher optical 
densities than the WT strain in all concentrations of phenol (Supplemental Table S1), had shorter 
lag phases in higher concentrations of phenol (Supplemental Table S2) and demonstrated growth 
even in 2 g/l phenol. White diamonds, gray squares and black triangles represent WT, evol33 and 
evol40, respectively. Data show the average of six biological replicates grown in 96 well plates 






Figure A1.2: Characterization of lipid accumulation.  
Comparison of total lipid (Nile red fluorescence) productivity between WT and the adapted strains. 
For all experiments, the nitrogen source was 0.05 g/l ammonium sulfate and an initial OD600 was 
0.3 with a culture volume of 10 ml. White bar = WT, gray bar = evol33 and black bar = evol40. 
Glucose = 1 g/l, Low Phenol = 0.75 g/l and High Phenol = 1.5 g/l. The data are the average of the 
arithmetic means of the Nile red fluorescence distribution obtained from three biological 
replicates. To take into account differences in the lag phase for each condition, time points were 
taken from the exponential to the stationary phase to determine the average increase in Nile red 
fluorescence over time for each condition. The asterisk indicates significant increases in lipid 
productivity compared to that of WT in the same condition (P < 0.05; one mean, two-tailed 
Student's t-test). No growth was observed for the WT strain in 1.5 g/l phenol (<1 cell doubling in 
10 ml cultures). Error bars represent one standard deviation with all staining and flow cytometry 





Figure A1.3: Transcriptomic and genomic information of genes involved in phenol 
degradation and utilization. 
(A) Transcriptomic and genomic information of genes involved in phenol degradation and 
utilization. Differential expression is shown for the phenol-responsive degradation operons, β-
ketoadipate pathway gene clusters, a putative phenol transporter gene and transcriptional regulator 
genes. Raw counts were normalized using variance stabilizing transformation in DESeq2 to fit in 
the range of 20 across all genes. Darker colors indicate higher normalized counts (as shown in 
Color Key). Glc, 1 g/l glucose; LowP, 0.75 g/l phenol; and HighP, 1.5 g/l phenol. The color scheme 
is the same throughout Figures Figures33 and 4 for each step of the pathway. Each square on the 





Figure A1.4 Pathway and genome maps showing genes involved in phenol degradation and 
utilization.  
(A) Ortho-cleavage branch of the β-ketoadipate pathway in R. opacus. An expanded pathway map 
including other phenol degradation pathways can be found in Supplemental Figure S10. The color 
scheme is the same throughout Figures 3 and 4 for each step of the pathway. (B) Genomic 
organization of the two phenol degradation operons. Light gray genes are highly upregulated in 










Supplemental Figure A1.1: Experimental approach.  
R. opacus PD630 wild-type (WT) strain was passaged in a minimal salts medium (MSM) with 
increasing concentrations of phenol as a sole carbon source, and an aliquot of the liquid culture 
was taken and stored at -80ºC at each passage. Of the 40 passages, 6 colonies per passage were 
purified from passages 17, 26, 33, and 40. Growth and lipid accumulation profiles of the isolated 
strains were analyzed, and two top performing colonies, evol33 and evol40, were chosen. WT, 




(Table 2 and Figure 3), and in-depth phenotyping including determination of growth profiles on 






















24 hr IC50 
(g/L) 
1.29 ± 0.10 1.49 ± 0.19 1.44 ± 0.11 15.5 11.6 
45 hr IC50 
(g/L) 
1.58 ± 0.08 1.90 ± 0.05 1.96 ± 0.06 20.3 24.1 
 
Supplemental Figure A1.2: Characterization of IC50 values for WT and adapted strains.  
Optical densities (OD600) measured from cultures grown in various concentrations of phenol and 
high nitrogen (1 g/L ammonium sulfate) at 24 and 45 hours were fitted in Prism using a four-
parameter inhibitor response curve to calculate the IC50 values. R2 values were greater than 0.88 































for all fittings. The fitted values for each biological replicate were averaged to calculate p values 
for significance (one mean, two-tailed Student’s t-test). IC50 values at 24 hours are not significantly 
different from WT for both adapted strains (p = 0.07 and p = 0.06 for evol33 and evol40, 
respectively), but IC50 values for both evol33 and evol40 at 45 hours are significantly higher than 
that of WT (p = 0.0004 and p = 0.0002 for evol33 and evol40, respectively). Error represents one 
standard deviation of fitted values from six biological replicates grown in 96 well plates. 

















Supplemental Figure A1.3: Growth and phenol consumption profiles of WT and adapted 
strains.  
Cells were grown in 100 mL of high nitrogen (1 g/L) minimal salts medium containing 1.5 g/L 
phenol as the sole carbon source. White diamonds = WT, gray squares = evol33, black triangles = 
evol40, and black square with white cross = no cell control (1.5 g/L phenol). A, Growth profile of 
WT and adapted strains. B, Phenol consumption profiles of WT and adapted strains. Phenol (g/L) 
was estimated by measuring absorbance of culture supernatants at 280 nm (see the Supplemental 
Materials and Methods). For both plots, each point is the average of three biological replicates and 












Supplemental Figure A1.4: Correlation between Nile red fluorescence and total lipid content 
(% CDW lipid).  
The WT strain was grown in four different ammonium sulfate concentrations (1, 0.2, 0.1, and 
0.025 g/L) as a sole nitrogen source and 1 g/L glucose as a sole carbon source for 24 hours. Three 
200 µL aliquots of each biological replicate were used for Nile red fluorescence measurement. 
Cells from each biological replicate were lyophilized, and the cell dry weight lipid content (% 
CDW lipid) of each biomass sample was calculated from the total lipids extracted using the Folch 
procedure (See Materials and Methods). The Nile red fluorescence values represent the average of 
three technical replicates from two biological replicates for a total of six replicates. The % CDW 
lipid values are the average of two biological replicates. The error bars represent the standard error.  
 


























Supplemental Figure A1.5: Nile red fluorescence and growth kinetics of WT and adapted 
strains.  
The top row shows the growth profile of each strain in low nitrogen conditions (0.05 g/L 
ammonium sulfate), and the bottom row shows the average Nile red fluorescence of each strain 
over time. No growth was observed for the WT strain in 1.5 g/L phenol with low nitrogen (<1 cell 
doubling in 10 mL cultures). Each data point represents the average of three biological replicates. 
Each Nile red fluorescence value is the arithmetic mean of the Nile red fluorescence distribution 
obtained using flow cytometry (see Materials and Methods for more information). Error bars 


















































































































































































Supplemental Figure A1.6: Lipid accumulation using lignin model compounds. 
Cultures were grown in 96 well plates at 200 µL volumes in low nitrogen (0.05 g/L) minimal 
medium using 1 g/L of total phenolics as a carbon source. Cells were harvested after 48 hours and 
analyzed for lipid content by Nile red analysis (see Materials and Methods). HBA = 4-
hydroxybenzoic acid, Benz = sodium benzoate, P+HBA+Benz = 1 g/L total phenolics; 0.33 g/L 
phenol, 0.33 g/L HBA, and 0.33 g/L Benz. e33 = evol33 and e40 = evol40. Stars represent 
significantly higher lipid accumulation compared to WT (p < 0.05, one tailed Student’s t-test). 
evol33 and evol40 show significantly higher lipid accumulation in phenol compared to WT (p = 
0.009 for evol33, p = 0.005 for evol40). However, the adapted strains do not show increased lipid 
production, compared to that of WT, on other lignin model compounds, although all strains have 
higher lipid accumulation using hydroxybenzoic acid and sodium benzoate as carbon sources than 
using phenol (p < 0.04 for all cases). Bars represent the average of five biological replicates, and 






























Supplemental Figure A1.7:  
Principal component analysis plot of all 8945 genes from RNA-Seq triplicate samples, generated 
by using the plotPCA function of DESeq2. Blue, WT; pink, evol33; green, evol40. Medium 









Bubble plot representation of fold changes in phenol degradation and utilization genes in low 
phenol (0.75 g/L). Sizes of the bubbles indicate log2 fold change compared to the same medium 
condition in WT, and colors indicate log2 fold change compared to the indicated adapted strain in 













Supplemental Figure A1.9: Expression profiles of other annotated phenolic degradation 
genes.  
Heat map of genes annotated as alternative phenol degradation pathways by RhodoCyc 
(http://rhodocyc.broadinstitute.org/) is shown. LPD gene IDs were converted from OPAG gene 






Supplemental Figure A1.10: Phenolic degradation pathways present in R. opacus PD630.  
Each enzymatic reaction is listed as a number that can be found in Supplemental Table S8 with 
enzyme name, E.C. number, and Gene ID number(s). Dotted lines represent alternate aromatic 
degradation pathways that could be involved in phenol degradation. A, Gentisate degradation 
pathway. B, Protocatechuate ortho-cleavage branch of b-ketoadipate pathway. C, Catechol ortho-
cleavage branch of b-ketoadipate pathway. D, Catechol meta-cleavage branch of b-ketoadipate 
































































Catechol Muconate Muconolactone 2-oxo-2,3-dihydrofuran-5-acetate




















































Supplemental Figure A1.11:  
Venn diagrams of genes >2-fold upregulated and < -2-fold downregulated in phenol in WT, 




genes with > |2|-fold changes in low phenol (0.75 g/L, LowP) and high phenol (1.5 g/L, HighP) 
compared to glucose are shown in the same strains. > |2|-fold upregulated and downregulated genes 








Supplemental Figure A1.12: Microscopy images of R. opacus PD630 under nitrogen-limited 
conditions. 
 The left four columns are epifluorescence micrographs of Nile red-stained, stationary phase R. 
opacus PD630 cells grown in nitrogen-limited conditions. The far-right column shows 





Supplemental Figure A1.13: MA Plot Summary.  
Each panel shows the up- or down-regulation of all genes in an indicated strain and medium 
composition compared to a different strain and medium composition. Expression difference of 
each gene is plotted as log2 fold change (y axis) and mean expression (x axis) of the gene. The 
gray dots represent insignificant fold changes in expression, and the red dots represent significant 
fold changes in expression where significance threshold is defined as the adjusted p value < 0.1 
(false discovery rate (Benjamini-Hochberg procedure) calculated using DESeq2 (Love et al., 






Supplemental Figure A1.14: Expression profile of Rsr and YRNA homologs in different 
growth conditions.  
Top, Rsr homolog expression profile. Raw counts were normalized using the plotCounts function 
in DESeq2 (Love et al., 2014) and plotted using Beeswarm package (https://cran.r-




region upstream of LPD06269 (predicted YRNA). Glc, 1 g/L glucose; LowP, 0.75 g/L phenol; and 





                         
Supplemental Figure A1.15: Calibration curve obtained by using known concentrations of 









































Supplemental Table A1.1: Comparison of WT, evol33, and evol40 maximum biomass 
accumulation.  
Initial OD600 was 0.01, and cells were grown in high nitrogen conditions (1 g/L ammonium 
sulfate). Biomass accumulation values reported are the highest attained OD600 value after 45 hours 
of growth. Significance was determined by a one mean, two-tailed Student’s t-test (p < 0.05). Error 
represents one standard deviation of six biological replicates grown in 96 well plates. Improvement 




















0.75 0.33 ± 0.03 0.45 ± 0.03 0.44 ± 0.04 Yes, both 36.1 32.5 
1 0.40 ± 0.06 0.48 ± 0.05 0.48 ± 0.04 Yes, both 21.5 22.0 
1.25 0.39 ± 0.07 0.52 ± 0.05 0.53 ± 0.05 Yes, both 32.2 33.4 
1.5 0.27 ± 0.04 0.52 ± 0.06 0.55 ± 0.06 Yes, both 92.3 102.4 
1.75 0.18 ± 0.05 0.35 ± 0.04 0.44 ± 0.03 Yes, both 92.3 145.9 










Supplemental Table A1.2: Comparison of WT, evol33, and evol40 lag phase. 
Initial OD600 was 0.01, and cells were grown in high nitrogen conditions (1 g/L ammonium 
sulfate). Lag phase was calculated as the time for more than two doublings to occur (OD600 > 0.04). 
Significance was determined by a one mean, two-tailed Student’s t-test (p < 0.05). Error represents 
one standard deviation of six biological replicates grown in 96 well plates. Improvement was 




















0.75 4.7 ± 2.4 3.3 ± 1.3 3.8 ± 0.1 No 28.4 18.2 
1 7.9 ± 5.7 6.6 ± 5.1 3.8 ± 0.1 No 17.3 51.9 
1.25 10.7 ± 5.7 7.2 ± 6.4 6.6 ± 5.1 No 32.6 38.6 
1.5 17.3 ± 2.7 9.3 ± 5.9 11.5 ± 5.0 Evol33 only 46.4 33.6 
1.75 25.4 ± 4.3 14.2 ± 5.2 12.0 ± 5.1 Yes, both 44.3 52.6 












Supplemental Table A1.3: Comparison of WT, evol33, and evol40 growth rates.  
Initial OD600 was 0.01, and cells were grown in high nitrogen conditions (1 g/L ammonium 
sulfate). Specific growth rates were calculated from fitting optical density measurements in the 
exponential phase.  Significance was determined by a one mean, two-tailed Student’s t-test (p < 
0.05). Error represents one standard deviation of six biological replicates grown in 96 well plates. 
The fitted values for each biological replicate were averaged to calculate p values for significance. 
N/A = not applicable. * = not enough growth to calculate accurate growth rate. Improvement was 




















0.75 0.06 ± 0.01 0.08 ± 0.03 0.07 ± 0.01 No 27.6 9.7 
1 0.09 ± 0.02 0.12 ± 0.01 0.11 ± 0.02 evol33 only 27.7 12.8 
1.25 0.08 ± 0.02 0.11 ± 0.02 0.12 ± 0.03 Yes, both 39.3 48.6 
1.5 0.07 ± 0.01 0.09 ± 0.01 0.10 ± 0.02 Yes, both 29.6 37.7 
1.75 0.08 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 No 12.0 8.0 










Supplemental Table A1.4: Maximum Nile red fluorescence in stationary phase.  
Nile red fluorescence was measured using flow cytometry as described in Materials and Methods. 
Significance was determined by a one mean, two-tailed Student’s t-test (p < 0.05). Error represents 
one standard deviation of three biological replicates. Improvement was calculated as (evolX-WT) 
/ WT x 100%, where X = 33 or 40. N/A = not applicable. ** = no significant growth (< 1 cell 
doubling in 10 mL cultures). Glc = 1 g/L glucose, LowP = 0.75 g/L phenol, and HighP = 1.5 g/L 


















Glc 355 ± 25 396 ± 43 413 ± 63 No 12 16 
LowP 205 ± 33 519 ± 51 393 ± 62 Yes, both 153 92 















Supplemental Table A1.5: Overall lipid productivity as measured by Nile red fluorescence.  
Productivity was calculated as the change in Nile red fluorescence divided by time elapsed, 
including a minimum of four time points. Significance was determined by a one mean, two-tailed 
Student’s t-test (p < 0.05). Error represents one standard deviation of three biological replicates. 
Improvement was calculated as (evolX-WT) / WT x 100%, where X = 33 or 40. N/A = not 
applicable. ** = no significant growth (< 1 cell doubling in 10 mL cultures). Glc = 1 g/L glucose, 
LowP = 0.75 g/L phenol, and HighP = 1.5 g/L phenol. Cells were grown in low nitrogen conditions 


















Glc 8.4 ± 2.3 8.2 ± 1.6 7.8 ± 2.4 No N/A N/A 
LowP 5.8 ± 1.4 13.6 ± 1.0 8.9 ± 0.9 Yes, both 134 53 













Supplemental Table A1.7: Differentially regulated genes in WT and adapted strains.  
A, The number of genes with indicated fold change in specified strains and conditions. Glc = 1 
g/L glucose, LowP = 0.75 g/L phenol, and HighP = 1.5 g/L phenol. Lists of greater than 8-fold 
upregulated or downregulated genes with DESeq2 results are shown in Supplemental Table S6 

















Fold change > 4 > 8 >16 >256 < -4 < -8 < -16 < -256 
WT LowP vs. Glc 395 164 85 7 592 318 180 9 
evol33 LowP vs. Glc 302 112 70 13 287 90 38 2 
evol40 LowP vs. Glc 327 141 74 8 564 253 101 1 
evol33 HighP vs. Glc 411 200 118 16 507 220 101 0 
evol40 HighP vs. Glc 440 197 116 10 721 348 166 10 
         
 > 8-fold upregulated < 8-fold downregulated 
WT LowP vs. Glc 22.83 22.23 
evol33 LowP vs. Glc 34.58 18.26 
evol40 LowP vs. Glc 25.47 16.76 
evol33 HighP vs. Glc 30.92 16.93 




Supplemental Table A1.8: Annotation for phenolic degradation pathways present in R. 
opacus PD630 (Supplemental Figure S10). NA = none annotated.  
# in Fig 
S10 Enzyme name E.C.# Gene IDs 
1 phenol hydroxylase 1.14.13.7 PD630_LPD06575 + PD630_LPD06576, PD630_LPD6740 + PD630_LPD06741 
2 catechol 1,2-dioxygenase 1.13.11.1 PD630_LPD06568, PD630_LPD06742 
3 muconate cycloisomerase I 5.5.1.1 PD630_LPD06567 
4 muconolactone D-isomerase 5.3.3.4 PD630_LPD06566 
5 3-oxoadipate enol-lactonase 3.1.1.24 PD630_LPD05453 
6 succinyl-CoA:3-ketoacid-CoA 
transferase 
2.8.3.6 PD630_LPD05448 + PD630_LPD05449 
7 3-oxoadipyl-CoA thiolase 2.3.1.174 PD630_LPD05455, PD630_LPD06744 
8 
protocatechuic 3,4-
dioxygenase 1.13.11.3 PD630_LPD05450 + PD630_LPD05451 
9 
3-carboxymuconate 
cycloisomerase I 5.5.1.2 PD630_LPD05452, PD630_LPD07500 




11 gentisate 1,2-dioxygenase 1.13.11.4 PD630_LPD03773, PD630_LPD06029 
12 maleylpyruvate isomerase 5.2.1.4 PD630_LPD03771 
13 fumarylpyruvate hydrolase 3.7.1.20 PD630_LPD03774, PD630_LPD06028 































Supplemental Table A1.9: Growth rate, lag phase, and maximum optical density of best-
performing strains obtained from colony purification.  
Cells were grown in 50 mL of minimal salts medium supplemented with 0.75 g/L phenol and 1 
g/L nitrogen source (initial OD600 = 0.05). See the Materials and Methods for information on the 
calculation of growth rate and lag phase.   
Strain Specific Growth Rate (hr-1) Lag Phase (h) Max OD600 
WT 0.107 27 0.55 
33-2 (evol33) 0.149 17 0.66 
33-3 0.127 17 0.65 
40-1 (evol40) 0.135 17 0.75 
40-2 0.133 17 0.67 
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